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1 Summary 
Bitter acids (BA) from the hop plant Humulus lupulus L. exhibit multiple beneficial 
biological properties. However, no studies are available regarding the effects of 
hop bitter acids on liver cells or chronic liver diseases, respectively. 
Chronic liver diseases are accompanied by chronic hepatic inflammation which 
can lead to liver fibrosis. If left untreated, liver fibrosis can progress to cirrhosis, 
which can cause liver failure. Importantly, cirrhosis is also the main risk factor for 
the development of hepatocellular carcinoma (HCC). Both cirrhosis and HCC are 
associated with high morbidity and mortality, and up until now, no effective 
treatment options are available.  
The aim of this thesis was to assess the effects of BA on hepatic stellate cells, the 
central mediators of liver fibrosis, and on hepatocellular carcinoma cells. 
First, the effects of hop bitter acids on hepatic stellate cells (HSC) were analyzed. 
HSC were isolated from murine and human liver tissues and were incubated with a 
standardized hop bitter acid extract. At a concentration of 25 µg/ml hop bitter acids 
(BA) started to induce lactate dehydrogenase leakage. Already at lower 
concentrations BA led to a dose dependent inhibition of HSC proliferation and 
inhibited IκB-α-phosphorylation and nuclear p65 translocation in a dose dependent 
way. Accordingly, the same doses of BA inhibited the expression of pro-
inflammatory and NFκB-regulated genes, but did not affect expression of genes 
not related to NFκB signaling. In addition to these effects on activated HSC, BA 
inhibited the in vitro activation of non-activated HSC as evidenced by delayed 
expression of collagen I and α-sma mRNA and protein. Together, these findings 
indicate that BA inhibit NFκB activation, and herewith, the activation and 
development of pro-fibrogenic phenotype of HSC in vitro.  
Next, we analyzed the effects of BA on hepatocellular carcinoma (HCC) cells. 
Here, we used two different standardized BA extracts enriched for either α-acids 
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or β-acids to get a first insight whether biological activity vary between these two 
groups of bitter acids. At a concentration of 25 µg/ml, only the β-acid rich extract 
started to induce aspartate aminotransferase (AST) release as marker for cell 
injury, whereas at a dose of 50 µg/ml both extracts led to a significant increase of 
AST liberation. Already at lower concentrations both extracts dose-dependently 
inhibited proliferation and migration of HCC cells. Analysis of different signaling 
pathways revealed an inhibition of ERK1/2 phosphorylation, down-regulation of 
AP-1 activity and an alleviation of NFκB activity in HCC cells in vitro. Hereby, the 
β-acid rich extract showed more pronounced effects. 
Furthermore, the stability of BA in a rodent chow supplemented with an α-acid rich 
extract was assessed applying high pressure liquid chromatography diode array 
detection technology. Mimicking feasible storage conditions we observed a very 
poor recovery, indicative of a strong degradation of BA. This prompted us not to 
proceed with application of this particular BA supplemented chow in rodent 
models, since in addition to imprecise BA-concentration also potential ill-defined 
degradation products would not have allowed a sound interpretation of such 
studies. 
In conclusion, hop bitter acids alleviate the pro-fibrogenic phenotype of hepatic 
stellate cells and inhibit central signaling pathways, which are known to play 
important roles in tumor development and progression, in hepatocellular 
carcinoma cells. These data suggest the potential use of hop bitter acids as 
functional nutrient or therapeutical agent for both prevention and treatment of 
chronic liver diseases. Further studies are needed to verify the beneficial effects in 
experimental models of liver injury in vivo. However, analysis of a newly designed 
BA-supplemented experimental chow for rodents revealed strong degradation 
processes even under optimal storage conditions. Therefore, special care has to 
be taken when planning long term BA-application experiments. 
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2 Introduction 
2.1 Botany 
The hop plant Humulus lupulus L. is a member of the small family Cannabaceae 
which consists only of two genera Humulus and Cannabis. The genus Humulus 
comprises three species, Humulus lupulus Lineus, Humulus japonicus Siebold & 
Zucc. and Humulus yunnanensis Hu. Originally, this genus belonged to the order 
Urticales but in 2003 it was incorporated to Rosales (Van Cleemput et al., 2009a; 
Zanoli and Zavatti, 2008). 
Humulus lupulus L. is a perennial herb that typically grows in the moderate climatic 
zones of the Northern and Southern hemispheres. During spring the plant regrows 
from the primary root with her succulent rhizome generating twining stems which 
can reach a height of about 10 meters. This climbing property was determinative 
involved in its naming as the Roman naturalist Plinius described the plant as “the 
wolf of the willow” (“lupus salictarius”) (Van Cleemput et al., 2009a). For him, wild 
hop grow behaviour was comparable with a wolf who raptures a sheep. The hop 
plant is dioecious and almost all seen cultivated hop are female individuals of the 
species Humulus lupulus L. because the female inflorescences (strobiles, cones) 
contain the lupulin powder which has been traditionally used as a preservative and 
flavouring agent in beer (Milligan et al., 2002). The selection of plants with specific 
organoleptic properties for a long time caused the existence of hundreds of named 
cultivars and recognized chemotypes (Zanoli and Zavatti, 2008). Harvesting time 
is from August till September when the amount of lupulin has reached its 
maximum level. Cultivation technique and a flowering female hop plant with 
inflorescences are shown in Figure 2.1.  
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Figure 2.1 (A) Cultivation of hop in long rows with supporting aids to allow vertical growth. (B) 
Female plant rich in inflorescences. 
 
The fine yellow secreted resinous powder (lupulin) is synthesized in the lipophilic 
lupulin glands, a peltate-type of glandular trichomes, which are located on the 
abaxial surfaces of the cone bracts and leaves with the highest affinity to the basal 
part of the bracteols as seen in Figure 2.2 A. The lupulin glands consist of four 
basal cells, four stalk cells and one large glandular head cell with a typical 
diameter of 100 – 200 µm (Oliveira et al., 2008). They originate from single 
epidermis cells after multiple cell divisions and lupulin is secreted in the cuticle-
enclosed cavity as seen in Figure 2.2 B (Wärtgen, 1990).  
 
 
 
Figure 2.2 (A) A single bract with many trichomes, mainly lupulin glands. (B) Close-up view on 
lupulin glands. 
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2.2 Hop Chemistry 
2.2.1 Lupulin ingredients 
Lupulin is rich in secondary metabolites which can be mainly classified as bitter 
acids, volatile oil, and polyphenols as listed in table 2.1.  
 
Table 2.1: Average Composition of Air-Dried hop cones 
 
From Cleemput et al. (Van Cleemput et al., 2009a). 
 
The volatile oil is the principal aroma component in hop (Wang et al., 2008). It is 
composed of a complex mixture of components, mainly terpenoids such as β-
myrcene (monoterpene), β-caryophyllene, farnesene and humulene 
(sesquiterpenes). The terpenoids account for more than 90 % of the total hop oil 
(Van Cleemput et al., 2009a; Zanoli and Zavatti, 2008). Lupulin-associated 
polyphenols are rich in prenylated chalcones with xanthohumol (XN) as main 
constituent (0.1 – 1 % of dry weight) (Zanoli and Zavatti, 2008). Under thermal 
isomerization XN converts to the prenylflavanone isoxanthohumol which is the 
main flavonoid in beer. Another encountered prenylchalcone in beer is 
desmethylxanthohumol, which is the precursor of 8-prenylnaringenin, the most 
potent phytoestrogen known to date (Milligan et al., 2002). Hop bitter acids are the 
Compound Percentage (m/m) 
α-acids 2 - 17 
β-acids 2 - 10 
amino acids 0.1 
ash/salts 10 
cellulose-lignin  40 - 50 
monosaccharides  2 
oils and fatty acids 1 - 5 
pectins  2 
polyphenols and tannins 3 - 6 
proteins  15 
volatile oil  0.5 - 3 (v/m) 
water 8 - 12 
Introduction  6 
quantitatively dominating secondary metabolite in the lupulin glands (about 30 %) 
and as object of this work will be now explained in more detail. 
 
2.2.2 Hop bitter acids 
The use of hop cones in beer brewing has a long history since it is known that hop 
has preservative and flavouring properties. Most of these properties are attributed 
to the hop bitter acids (BA).  
BA consist of two related series, the α-acids or humulones and β-acids or 
lupulones, which are both characterized as prenylated acylphloroglucinols (Van 
Cleemput et al., 2009a). The two series comprise five analogues each, depending 
on the nature of the acyl side chain at position C6 as shown in Figure 2.3. The 
side chains are derived from the hydrophobic amino acids, leucine, valine and 
isoleucine (Keukeleire D.D., 2000). The analogues are termed humulone / 
lupulone, cohumulone / colupulone, adhumulone / adlupulone, prehumulone / 
prelupulone, posthumulone / postlupulone, respectively (Van Cleemput et al., 
2009a). The chemical structure of humulone was uncovered by Heinrich Wieland 
1925, whereas lupulone was uncovered by Wöllmer (1916 and 1925) and Wieland 
(1925) (Wöllmer, 1916, 1925; Wieland, 1925). 
 
Figure 2.3 Basic structures of hop bitter acids and main side chains. 
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The amount of BA in hop cones strongly depend on strain, cultivation condition 
and harvesting time, but in general the analogues n-humulone, cohumulone, and 
adhumulone are the main constituents of hop α-acids, representing 35 – 70 %, 20 
– 65 %, and 10 – 15 %, of total levels, respectively (Van Cleemput et al., 2009a). 
The amount of lupulone and colupulone are similar representing 20 – 55 % and 
adlupulone with 10 – 15 % of total levels, respectively (Van Cleemput et al., 
2009a). Prehumulone / prelupulone and posthumulone / postlupulone are only 
present in trace quantities. 
In beer brewing, BA are added to wort (filtrated sugar solution obtained after 
enzymatic reaction of the so called mash) and boiled at least for one hour. After 
removal of BA, the so called “hoppy wort” is fermented using different yeast 
strains. Importantly, genuine bitter acids can be found only in trace amounts in 
beer, that are 4mg/L for α-acids and only minor amounts of β-acids (Van Cleemput 
et al., 2009a). This is based on the fact that BA are extremely sensitive to 
oxidation as well as their bad solubility in water (wort; pH 5.0 – 5.5). α-acids are 
the most important compounds responsible for the bitter taste. During wort boiling, 
α-acids transform to iso-α-acids or isohumulones via an acyloin-type ring 
contraction (Keukeleire D.D., 2000). Each of the three main α-acids transform into 
two epimeric iso-α-acid analogues. These iso-α−acids are more water soluble 
yielding concentrations ranging from 10 up to 100 mg/L in beers without significant 
differences in their bitterness (Van Cleemput et al., 2009a; Pollock, 1979). 
Because of their solubility, iso-α-acids account for 80% of total hop derived 
components in beer. They are responsible for the bitter flavour and due to their 
tensioactive properties, are also important in foam stability. Therefore, 
transformation of α-acids to iso-α-acids is the most important reaction in hop 
chemistry (Pollock, 1979). Otherwise, under exposure of light iso-α-acids 
decompose, generating three major derivatives called dihydro-, tetrahydro- and 
hexahydro-iso-α-acids, respectively. This decomposition generates skunky thiols 
as byproducts which are responsible for the “lightstruck” flavour of beer. Therefore, 
beer is generally stored in lightproofed bottles (Van Cleemput et al., 2009a). β-
acids are more sensitive to oxidation, transforming in the very stable hulupones 
which are very bitter. However due to their low quantity they play only a minor role 
in beer quality (Van Cleemput et al., 2009a).  
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Because of the importance of iso-α-acids for the bitterness of beer and because of 
the high susceptibility to oxidative degradation of BA in general, different isolation 
techniques were developed over the last decades. One effective isolation 
technique of BA is their separation from hop cones by extraction with supercritical 
carbon dioxide under high pressure. The obtained extracts contain high levels of 
α-acids and β-acids without the more polar tannins, hard resins, and salts (Van 
Cleemput et al., 2009a). Further characterization of the extract using high pressure 
liquid chromatography (HPLC) allows a specific determination of the composition 
of BA, making them an attractive instrument for controlling organoleptic features in 
beer brewing. 
 
2.3 Biological effects of hop bitter acids 
2.3.1 Anti-bacterial effects 
Beer is a beverage with high microbiological stability and only a limited number of 
species of microorganisms have been reported to spoil beer (Suzuki et al., 2006). 
This bacteriostatic activity is mainly attributed to BA. First evidences for the anti-
bacterial properties of BA were provided in the middle of the 20th century. BA are 
able to inhibit growth of gram positive bacteria including species of Bacillus, 
Lactobacillus, Micrococcus, Staphylococcus and Streptococcus, whereas gram-
negative bacteria are either resistant or only affected at very high concentrations 
(Van Cleemput et al., 2009a; Shimwell, 1937; Teuber and Schmalreck, 1973). In 
general, β-acids have higher bacteriostatic activity then α-acids (Lewis et al., 
1949). A work by Teuber further demonstrated that the two epimeric iso-humulone 
analogues exhibit less potency against gram-positive bacteria than lupulone and 
humulone, respectively (Teuber, 1970). Another study by Teuber and Shamwell 
highlighted that the plasma membrane of susceptible bacteria is the primary target 
of BA and that the incorporation potency of BA in the cell membrane correlates 
with their hydrophobicity (Teuber and Schmalreck, 1973). Importantly, Simpson 
and Smith realized that the pH value is an important determinant of the anti-
bacterial activity of BA and that previous studies did not consider this factor. They 
identified isohumulone to be the most potent inhibitor of bacterial growth at a pH 
value between 3.8 and 4.4 which is typical for beer (Simpson and Smith, 1992). 
Introduction  9 
BA act as mobile carrier ionophores for undissociated molecules to enter the cell. 
As BA are weak acids they are only able to bind these molecules in their un-
ionized form which in turn is pH depended (Van Cleemput et al., 2009a). Further 
studies by Chin and colleagues demonstrated the inhibitory effect of lupulone on 
Mycobacterium tuberculosis in vitro and in vivo (Chin et al., 1949b; a). 
Interestingly, a study by Farber and colleagues confirmed the therapeutical effect 
of lupulone in ten patients suffering from tuberculosis (Farber et al., 1950). 
However, the number of cases was very small.  
It has to be noted that BA also have anti-fungal properties but yeast is not affected 
by BA which highlight the utility of BA as preserving agent in beer (Mizobuchi and 
Sato; Michener et al., 1948; Srinivasan et al., 2004). 
 
2.3.2 Anti-inflammatory effects 
One of the first experiments identifying the anti-inflammatory potency of hop was 
done by Yasukawa and co-workers in 1993 (Yasukawa et al., 2006). They 
screened about 100 edible plant extracts for their anti-inflammatory capability in 
12-O-tetradecanoylphorbol-13-acetate (TPA) induced ear oedema in mice. 
Interestingly, hop showed to be the most potent inhibitor of TPA induced 
inflammation. A repetition of the experiment with purified humulone revealed an 
ID50 value of 0.2 mg/ear which was similar to the inhibitory potency of 
indomethacin (ID50 0.3 mg/ear).  
A key component in inflammation is the increase of prostanoids, including 
prostaglandin E2 (PGE2) which results from the transformation of arachidonic 
acid. In general, two isozymes of prostaglandin forming cyclooxygenases are 
known, the constitutively expressed cyclooxygenase 1 (COX-1) and the inducible 
cyclooxygenase 2 (COX-2) (Yamamoto et al., 2000). The induction of COX-2 is 
triggered by pro-inflammatory mediators and mitogenic stimuli including cytokines, 
endotoxins, growth factors, oncogenes and phorbol esters (Surh et al., 2001; Hall 
et al., 2008). Therefore, COX-2 is considered to function primarily as mediator of 
inflammation and pain in inflamed tissues whereas the housekeeping enzyme 
COX-1 is thought to be involved in homeostatic function such as cytoprotection of 
the gastric mucosa or regulation of renal blood flow and platelet activation (Hall et 
al., 2008).  
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Several studies with individual hop acids demonstrate their anti-inflammatory 
potency, by selectively inhibiting COX-2 up-regulation upon pro-inflammatory 
stimuli (Van Cleemput et al., 2009a). Humulone dose-dependently suppressed 
tumor necrosis factor α (TNFα) induced PGE2 release in murine osteoblastic 
MC3T3-E1 cells (IC50 30 nM) (Yamamoto et al., 2000). The authors further 
demonstrated that humulone dose-dependently suppressed TNFα induced COX-2 
mRNA expression and protein activity albeit the IC50 level for the catalytic activity 
was about two orders magnitude higher than the IC50 for transcription. Thus, 
humulone seems to modulate COX-2 at the transcriptional level, and further 
analysis revealed that nuclear factor kappa B (NFκB) and NF-IL6 are involved. 
However, the observed effects were independently of glucocorticoid receptors. 
Importantly, humulone did not affect COX-1 activity which indicates its low 
gastrointestinal toxicity, a problem of most nonsteroidal anti-inflammatory drugs 
(NSAIDs) (Van Cleemput et al., 2009a). Hougee and co-workers showed that a 
standardized hop extract (18.1 % α-acids containing 71.8 % humulone; 2.3 % β-
acids) was able to inhibit PGE2 production in lipopolysaccharide (LPS) stimulated 
human peripheral blood mononuclear cells without affecting the metabolic activity 
as marker for cytotoxicity (IC50 3.6 µg/ml) (Hougee et al., 2006). They further 
demonstrated that the hop extract selectively inhibited COX-2 but not COX-1 
activity using specific COX-1 (SC-560) and COX-2 (celecoxib) inhibitors in whole 
blood assays (WBA). Interestingly, orally administered hop extract failed to 
diminish joint swelling in a zymosan induced acute arthritis model in mice. 
However, ex vivo blood cells from hop treated mice stimulated with LPS showed 
24 % lower PGE2 levels compared to control blood cells. In another study, an 
isomerized α-acid extract (IHE) and pure isohumulone were applied to murine 
macrophage RAW 264.7 cells, which were stimulated with LPS and interferon γ 
(INFγ). Both hop products dose-dependently inhibited the LPS and INFγ induced 
PGE2 production (Nozawa et al., 2005). Further, feeding rats with IHE (0.01 % 
and 0.04 %) for one week after treatment with azoxymethane (AOM four injections 
within four weeks) significantly reduced PGE2 level in colonic mucosa. Similar 
observations with rho-iso-α−acids (RIAA), a manmade defined mixture of reduced 
isohumulones using sodium borohydride, where obtained by Hall and colleagues. 
They demonstrated a dose-dependent suppression of LPS induced PGE2 release 
and COX-2 expression in RAW 264.7 macrophages without toxicity effects on a 
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gastric mucosal cell line (Hall et al., 2008). Another study analyzed if tetrahydro-
iso-α-acids (called META060) targets pre-built COX-2 protein in LPS triggered 
RAW 264.7 cells. META060 failed to abrogate pre-built COX-2 induced PGE2 
levels (Desai et al., 2009), which confirmed the assumption that BA inhibit COX-2 
at the site of transcription.  
Several studies identified the underlying molecular mechanism of the anti-
inflammatory potency of individual hop extracts. Using the phorbol ester mouse 
skin model, Lee and colleagues identified NFκB and activator protein-1 (AP-1) 
pathways as direct targets of humulone mediated COX-2 suppression in TPA 
treated mouse skin (Lee et al., 2007).  
NFκB functions as a major transcription factor in inflammatory responses and its 
activation is often detected in cancer (Vallabhapurapu and Karin, 2009). In its 
inactive form, NFκB consists of a heterotrimer composed of two members of the 
RelA family (mainly p50 and p65) which are bound to members of the IκB family 
(mainly IκBα) which function as inhibitors. This heterotrimer is located in the 
cytoplasm. Pro-inflammatory stimuli lead to phosphorylation of IκBα by protein 
kinase complex IKK and in turn to its ubiquitination and rapid degradation. The 
active heterodimer translocate into the nucleus and activate NFκB related genes 
(Vallabhapurapu and Karin, 2009). Lee and co-workers identified IKK as direct 
target of humulone with greater extend on IKKβ than IKKα acitivity. Furthermore, 
humulone exhibited modulatory effects on several kinases. The mitogen-activated 
protein kinases (MAPK) ERK, p38 and JNK were blunted by humulone (Lee et al., 
2007). Desai and colleagues demonstrated a direct functional effect of META060 
on LPS induced NFκB binding properties in reporter gene assays. Furthermore 
META060 inhibited members of the family of Tec tyrosine kinases, particularly 
BTK (IC50 41 µg/ml), SyK (IC50 60 µg/ml) and BMX (IC50 87 µg/ml) as evidenced in 
enzyme free cell assays. Members of this family are important for effective LPS 
triggering of macrophages (Desai et al., 2009). Van Cleemput and colleagues 
compared α-acids, β-acids and iso-α-acids for their anti-inflammatory potency on 
L929sA fibroblasts (Van Cleemput et al., 2009b). BA were able to alleviate TNF 
induced cytokine interleukin-6 (IL-6) mRNA and protein as well as pro-
inflammatory chemokine RANTES transcription. The suppression efficiency of α- 
and β-acids (1-5 µM) was more potent compared to iso-α-acids (50-100 µM). 
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Further, BA dose-dependently repressed TNF-induced promoter activities of the 
NFκB-dependent genes IL8 and E-Selectin compared to a synthetic triple κB 
repeat (α-acids, IC50 0.78 µM; β-acids, IC50 0.70 µM; iso-α-acids IC50 37.04 µM). 
Many cytokines including IL-6 have binding sites in their promoter region for the 
pro-inflammatory transcription factors AP-1 and CREB (Van Cleemput et al., 
2009b). Reporter gene assays revealed a dose-dependent inhibition of both 
transcription factors by BA. Intraperitoneal injection of α-acids and iso-α-acids 
(250 µg each) in zymosan induced inflammation of the footpad markedly alleviated 
the swelling which persists up to 24 h. In another approach lupulone was tested in 
a model of colon carcinogenesis. The formation of preneoplastic lesions was 
initiated by AOM. Orally administered lupulone was able to reduce the amount of 
lesions. Further analysis of inflammatory cytokines IL-1β and TNFα revealed a 
reduced expression after lupulone administration (Bousserouel et al., 2011).  
 
2.3.3 Anti-cancer effects 
Several natural compounds including hop bitter acids have gained considerable 
attention as chemopreventive agents. Chemoprevention is recognized as 
pharmacological intervention to prevent, inhibit or reverse carcinogenesis or to 
prevent the development of invasive cancer using synthetic or natural agents (She 
et al., 2003). The first hint for chemopreventive properties of BA was found by 
Yasukawa and co-workers in the year 1993 since inhibitors of TPA-induced 
inflammation such as humulone, seem to be roughly in parallel with their inhibitory 
activities on tumor promotion (Yasukawa et al., 2006). 
One strategy in cancer therapy is the specific induction of apoptosis in cancer cells 
(Thompson, 1995). Apoptosis or programmed cell death is a mechanism that is 
highly conserved from lower eukaryotes to mammals. It involves the activation of 
caspases (cystein proteases) which cleave a variety of cellular substrates that 
contribute to biochemical changes and eventual cell destruction (Chen and Lin, 
2004). At least two pathways of caspase activation are known. The extrinsic 
pathway involves death receptors (Fas, TNFR, DR3, DR4 and DR5) and the 
intrinsic pathway involves disruption of the mitochondrial membranes driven by 
Bcl-2 family proteins. Tobe and colleagues demonstrated that humulone (1-
100 µg/ml) time- and dose-dependently induced DNA fragmentation in the human 
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leukemia cell line HL-60. The authors therefore suggested that humulone has 
apoptosis-inducing activity in this cancer cell line. Further studies tried to unravel 
underlying molecular mechanisms. Chen and Lin used a defined hop extract 
containing 49.39 % α-acids and 24.94 % β-acids (Chen and Lin, 2004). BA dose-
dependently inhibited cell viability of HL-60 cells (IC50 8.67 µg/ml) and to a lesser 
extent of human histolytic lymphoma U937 cells (IC50 58.87 µg/ml). Further 
analysis showed that BA induced DNA fragmentation in both cell lines which was 
in part mediated by disruption of the mitochondrial membrane as demonstrated by 
mitochondrial membrane potential measurement, mitochondrial cytochrome c 
release, active caspase-9 protein level and alteration of Bcl-2 family proteins. 
Furthermore, BA increased the death receptor FAS and its ligand FASL and 
downstream activation of caspase-8 and Bid. Similar observations were obtained 
by Lamy and colleagues (Lamy et al., 2007). Lupulone increased mitochondrial 
membrane permeability by alteration of Bcl-2 family expression. Furthermore, they 
identified modulation of FAS and FASL as well as TNF-related apoptosis inducing 
ligand (TRAIL)-R1 (DR4) and -R2 (DR5) receptor proteins in human colon cancer-
derived metastatic SW620 cells stimulated with lupulone. Interestingly, lupulone 
was able to up-regulate DR4 and DR5 in both TRAIL-sensitive (SW480) and 
TRAIL-resistant (SW620) cells suggesting that p53 plays only a marginal role in 
the lupulone triggered apoptosis (Lamy et al., 2010). Analysis of different MAPK, 
namely JNK, ERK and p38 using specific inhibitors revealed that only p38 plays a 
major role in lupulone triggered apoptosis (Lamy et al., 2011). Oral administration 
of lupulone (0.001 % and 0.005 %) led to a 30 and 50 % reduction in the formation 
of preneoplastic lesions induced by AOM in wistar rats respectively, which 
highlights the potential therapeutic use of lupulone in colon carcinogenesis (Lamy 
et al., 2007).  
Shimamura and co-workers analyzed the effect of humulone on angiogenesis 
which describes the formation of new capillary blood vessels (Shimamura et al., 
2001). Angiogenesis plays a key role in tumor formation. An important angiogenic 
factor is vascular endothelial growth factor (VEGF) which is often highly expressed 
in tumor cells. Humulone dose-dependently inhibited angiogenesis in chick 
chorioallantoic membranes (CAMs) in vivo (ED50 1.5 µg/CAM). Furthermore, 
humulone suppressed the proliferation of Kop2.16 endothelial cells and reduced 
the production of VEGF in Kop2.16 and Co26 tumor cells in vitro, respectively 
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(Shimamura et al., 2001). Similar observations with lupulone where obtained by 
Siegel and colleagues (Siegel et al., 2008). They demonstrated that lupulone is 
able to inhibit basal as well as VEGF and basic fibroblast growth factor (bFGF) 
induced proliferation of human umbilical vein endothelial cells (HUVEC). Further, a 
boyden chamber assay revealed that lupulone dose-dependently inhibited the 
migratory capacity of HUVEC. Moreover, lupulone reduced capillary-like tube 
formation of HUVEC in vitro and in Matrigel plugs implemented in mice in vivo, 
respectively. Honma and co-workers identified humulone as potent inhibitor of 
human leukemia U937 cell proliferation (IC50 3.4 µM) (Honma et al., 1998). 
Moreover, they demonstrated that humulone enhanced the differentiation of U937 
cells induced by vitamin D3, TPA, all trans retinoic acid and TNFα. These effects 
were similar in K562, HEL, Ku182, HL-60, THP-1 and ML-1 cells. The inhibition of 
proliferation and enhancement of differentiation of premalignant cells are expected 
to reduce cancer development (Van Cleemput et al., 2009a). 
 
2.3.4 Effects on lipid and carbohydrate metabolism 
The application of phytochemicals in foods and in isolated form to provide health 
benefits has gained more and more attention since metabolic diseases accelerate 
in the last decades. The so-called “metabolic syndrome” contains a cluster of 
abnormalities, including insulin resistance, glucose intolerance, dyslipidemia, 
hypertension, hyperinsulinemia, and microalbuminuria which when occur in 
combination can lead to heart disease and diabetes (Bruce and Hanson, 2010). 
Peroxisome proliferator-activated receptor family are dietary lipid sensors that 
regulate fatty acid and carbohydrate metabolism (Yajima et al., 2004). Modulation 
of PPARs using synthetic ligands such as fibrates for PPAR α and 
thiazolidinediones for PPAR γ are useful in the treatment of metabolic disorders 
(Kersten et al., 2000). Yajima and colleagues analyzed the effect of isohumulones 
on PPAR α and PPAR γ activation in vitro and in vivo (Yajima et al., 2004). All 
three main isohumulone analogues activated PPARs as evidenced in co-
transfection studies. Further, feeding isohumulone (0.18 % m/m) and 
isocohumulone (0.18 % m/m) over a period of two weeks prevented the 
development of hyperglycemia and hyperlipidemia in a mouse model of non-
insulin-dependent diabetes (KK-Aγ). BA were able to lower the plasma triglyceride 
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and free fatty acid levels compared to control fed mice, respectively. Moreover the 
nonfasting plasma glucose levels were reduced compared to control mice, 
respectively. Interestingly administration of BA did not alter body weight gain 
compared to a 10 % increase using the insulin sensitizer pioglitazone. Quantitative 
RT-PCR analysis revealed an up-regulation of acyl-CoA oxidase and fatty acid 
translocase genes in the liver after BA administration. In contrast, the expression 
of PPAR γ regulated genes coding for adipose differentiation related protein and 
for lipoprotein lipase were only slightly increased after isohumulone administration. 
However, isohumulones reduced adipocyte hypertrophy and induced apoptosis of 
hypertrophic adipocytes in white adipose tissue. In another approach C57BL/6N 
were fed a high fat diet to induce hyperglycemia and obesity. Short term co-
administration of isohumulone and isocohumulone alleviated insulin resistance 
and glucose intolerance. Miura and colleagues demonstrated that isohumulones 
alone and in addition with humulone and lupulone raised total HDL-cholesterol 
plasma levels and reduced plasma triglyceride content after administration of a 
high fat and cholesterol diet in mice (Miura et al., 2005). Liver contents of 
cholesterol and triglycerides were markedly reduced after BA administration. 
Quantitative RT-PCR analysis revealed an up-regulation of several hepatic genes 
involved in fatty acid oxidation, but no alteration of genes responsible for 
cholesterol synthesis and excretion. Similar results were obtained by Shimura and 
co-workers (Shimura et al., 2005). The administration of a standardized 
isohumulone extract in water in combination with a high fat diet significantly raised 
total HDL-cholesterol plasma levels and reduced the plasma triglyceride content. 
Microarray analysis identified Cyp4a14 as the most regulated gene after BA 
administration. The strong up-regulation of Cyp4a14 together with other members 
of the Cyp4a family suggests an increase in microsomal ω-oxidation. The fact, that 
these effects were abolished using PPAR α deficient mice indicates direct 
modulation of PPAR α through isohumulones. Recently, the influence of 
tetrahydro-iso-α-acids (called META060) was also examined in high fat diet 
induced obese and diabetic mice (Everard et al., 2012). META060 reduced high 
fat diet induced body weight gain and fat mass development (subcutaneous, 
visceral and epididymal). Further, META060 improved glucose tolerance and 
protected against insulin resistance and fasting hyperinsulinemia.  
 
Introduction  16 
2.3.5 Other effects 
Tagashira and co-workers analyzed the anti-oxidative activity of humulone, 
lupulone and two modified bitter acids (Tagashira et al., 1995). Humulone and 
lupulone showed radical scavenging activity with IC50 values of 32 and 25 µM, 
respectively. Furthermore both compounds inhibited lipid peroxidation activity 
(humulone IC50 7.9 µM; lupulone IC50 39 µM). Interestingly, BA were more potent 
than the antioxidant substances α tocopherol and ascorbic acid. Similar 
observations were achieved in another report. Here, the following order of radical 
scavenging activity was observed (IC50 [mg/ml]): α-acids 0.21; β-acids 0.96; 
dihydro-iso-α-acids 1.36; tetrahydro-iso-α-acids 1.40 and hexahydro-iso-α-acids 
1.78 (Liu et al., 2007). Namikoshi and co-workers demonstrated that a 
standardized isohumulone extract (isohumulone, isocohumulone, and 
isoadhumulone at a ratio of 37:48:15) is able to prevent renal tissue damage in 
rats after high salt diet. Isohumulone decreased renal reactive oxygen species 
(ROS) leading to the restoration of bioavailable nitric oxygen which in turn is 
important for salt and water homeostasis in the kidney (Namikoshi et al., 2007). 
Tobe and colleagues identified humulone to be a strong inhibitor of bone 
resorption (IC50 5.9 nM) in a pit formation assay (Tobe et al., 1997). Adhumulone 
showed a similar inhibitory effect whereas cohumulone showed almost no 
inhibitory activity. Thus, humulone might be a therapeutic agent for the treatment 
of osteoporosis. The authors suggested a role of the PI3K pathway. However, the 
underlying mechanism remains unclear. 
 
2.4 Toxicology 
In general, hop compounds are recognized as safe due to their long-time 
application in brewing and as herbal medicine. Some in vivo studies exhibited that 
only huge amounts of hop are toxic, which was demonstrated in frogs (Stavén-
Grönberg, 1927; Steidle, 1931). 
Soderberg and Wachtmeister analyzed the effect of repeated intravenous 
injections of humulone in cats and rabbits (Soderberg and Wachtmeister, 1955). 
Humulone (1-10 mg/kg) evoked hyperventilation and an increase in body 
temperature and when body temperature reached a level of 42 °C polypnoea 
appeared in cats. These observed effects were much weaker in rabbits. 
Introduction  17 
Interestingly, after death through humulone cats rapidly developed an abnormally 
severe rigor mortis which suggests that humulone affect muscular metabolism 
(Van Cleemput et al., 2009a).  
Nozawa and colleagues observed no signs of toxicity after oral administration of 
iso-α-acids (0.01-0.05 %) for seven weeks in rats (Nozawa et al., 2005). Further 
analysis by Yajima and co-workers revealed a significant decrease in serum GPT 
and GOT levels after iso-α-acids administration in mice (Yajima et al., 2004). 
Conversely, Miura et al. demonstrated no changes of the transaminase levels, 
albeit the relative liver weight was higher after BA treatment (Miura et al., 2005). 
The latter effect was also observed by Shimura and colleagues (Shimura et al., 
2005).  
Rho-iso-α-acids (RIAA) from hops are generally regarded as safe (Konda et al., 
2009). The only statistically significant change after oral administration of RIAA 
(250 mg/kg day) for 21 days to mice was the increase in absolute and relative liver 
weights. Histological examinations noted only minor changes in liver and spleen 
(Hall et al., 2008).  
Subchronic oral administration of tetrahydro-iso-α-acids and hexahydro-iso-α-
acids in dogs revealed that they are generally well tolerated with no-observed-
adverse-effect levels (NOAEL) using 50 up to 100 mg/kg body weight (Chappel et 
al., 1998). No histopathological changes were found but statistically significant 
increase in absolute and relative liver weight was observed. Further, serum 
alkaline phosphatase was increased after 13 weeks of BA administration and the 
authors suggested that it is from hepatic origin. Moreover, negative results were 
reported in a number of mutagenicitiy and genotoxicity tests with di-, tetra- and 
hexa-iso-α-acids, respectively.  
Only a small number of reports are available at present addressing the safety of 
hop bitter acids in humans. No toxicity of liver, kidney, bone marrow and 
myocardium was detectable in humans that ate 5 g lupulone daily for three months 
(Farber et al., 1950). However, every patient experienced some degree of gastro-
intestinal irritation after taking the first dose of the drug (10 times 0.5 g). These 
irritations included epigastric burning, abdominal cramping and sometimes water 
diarrhea that occurred from five minutes to six hours after intake. Another report 
with NG440, a defined mixture of phytochemical substances including RIAA, 
revealed no changes in blood pressure, amount of whole blood cells and fecal 
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calprotectin, a marker for gastrointestinal injury (Minich et al., 2007). A pilot trial 
with META050, a formula containing phytochemical substances and RIAA, also 
revealed no serious side effects after administration for eight weeks (Lukaczer et 
al., 2005). 
 
2.5 Effects of hop bitter acids on the liver 
The liver is the largest gland of the human body with several important functions. 
70 % of the blood supply comes from the gut via the portal vein. This blood is 
enriched with nutrients and other substances that were orally administered. 
Therefore, the liver plays a major role in regulation of carbohydrate (glucose 
degradation and glycogen storage) and lipid homeostasis (enterohepatic bile acid 
system, lipogenesis and lipid trafficking) in the body. It is further important in 
storage and detoxification, in synthesis of hormones and coagulation factors, 
production and decomposition of red blood cells and plasma protein synthesis, just 
to mention the most important functions.  
Parenchymal cells called hepatocytes are the most abundant cell type in the liver. 
They account for approximately 80 % of total liver cell mass (Kmieć, 2001). 
Hepatocytes can be polyploid with numerous mitochondria, and perform the 
majority of liver functions. The remaining 20 % consist of non-parenchymal cells 
which can be mainly classified in hepatic stellate cells (formerly called Ito cells), 
Kupffer cells (macrophages), liver sinusoidal endothelial cells (LSEC), liver-
resident lymphocytes and cholangiocytes. Hepatocytes build strong cell junctions 
between themselves and exhibit cell polarity. Their basolateral surface is directed 
to the sinusoidal blood vessels. These capillaries consist of LSEC which are 
fenestrated to enable direct contact between hepatocytes and sinusoidal blood. 
Hepatic stellate cells (HSC) are located in the perisinusoidal space (or space of 
Disse), the area between hepatocytes and endothelium. 
As mentioned in chapter 2.4 different reports noticed changes in relative liver 
weight and/or serum transaminases after feeding BA. However, there are only a 
few reports available which examined the influence of BA on the liver in more 
detail. 
Miura and colleagues analyzed the expression of several hepatic genes after 
administration of hop extracts in combination with high fat in mice (Miura et al., 
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2005). Quantitative RT-PCR analysis of genes involved in lipid metabolism 
revealed an up-regulation of HMG-CoA synthetase, LDL receptor, acyl-CoA 
oxidase, acyl-CoA synthetase, fatty acid transport protein, and lipoprotein lipase 
whereas apolipoprotein B and apolipoprotein CIII were decreased. In addition, no 
alteration of hydroxymethylglutaryl-CoA reductase and Cyp7A1 gene expression 
was observed. Shimura and co-workers confirmed these findings using microarray 
analysis. They further identified several hepatic genes, e.g. cytochrome P450 
genes like Cyp4A14 and Cyp4A10, to be regulated by BA (Shimura et al., 2005). 
Hall and co-workers identified the regulation of several cytochrome P450 genes, 
which are involved in the metabolism of phase I drugs and xenobiotics (Hall et al., 
2008). RIAA demonstrated a strong inhibition of Cyp2B9 (IC50 0.30 µg/ml), a 
moderate inhibition of Cyp2C19 (IC50 6.3 µg/ml) and a weak inhibitory effect on 
Cyp3A4 (IC50 12-14 µg/ml) while no inhibitory effect was noted at the highest 
concentration for Cyp1A2 (>100 µg/ml), Cyp2D6 (>100 µg/ml), and Cyp2E1 
(>50 µg/ml). Foster and colleagues analyzed the effect of 35 different sorts of beer 
on cytochrome P450 metabolism using rat microsomes (Foster et al., 2009). In this 
study most products showed little or moderate inhibitory effects on Cyp2C19, 
Cyp3A4, Cyp3A5, Cyp3A7 and Cyp3A19. Furthermore, a homogenous moderate-
to-strong inhibition of Cyp2C9 was observed by all sorts of beer. Moreover, 
correlations between BA content and Cyp inhibition demonstrated that β-acids can 
modulate Cyp3A4, Cyp3A5, Cyp3A7 and Cyp3A19 isozymes. Teotico et al. 
reported that colupulone and a hop extract were able to induce Cyp3A4, Cyp2B6 
and MDR-1 gene expression in human hepatocytes in vitro (Teotico et al., 2008). 
Cyp3A4 and Cyp2B6 are important in drug metabolism and MDR-1 plays a role in 
drug efflux. Interestingly, BA were able to activate active pregnane X receptor 
(PXR), a direct regulator of Cyp3A4 using reporter gene assays. Moreover, crystal 
structure x-ray analysis revealed a possible colupulone PXR interaction through 
which activation may occur.  
 
Up until now, a detailed analysis of hop bitter acids on hepatic stellate cells as key 
players in liver fibrosis, and data concerning the chemopreventive effects of BA on 
hepatocellular carcinoma are missing. 
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2.6 Liver diseases 
2.6.1 Definition and development 
Liver diseases describe any type of liver impairment that leads to incomplete liver 
function. They can be divided in acute liver diseases as a consequence of 
intoxication or acute infections and chronic liver diseases. The latter can be 
caused by chronic alcohol or drug abuse, genetic alterations, viral infections and 
by metabolic disorders or by any combinations thereof. Chronic hepatic injury 
leads to chronic hepatic inflammation which in turn can manifest in liver fibrosis. 
Liver fibrosis and its progressive stage called cirrhosis, outline the final common 
pathway of virtually all chronic liver diseases (Iredale, 2007). Importantly, the long-
standing damage of hepatocytes and chronic inflammation within the cirrhotic liver 
give rise to the development of most cases of hepatocellular carcinoma (80 %) 
(Alison and Lovell, 2005). 
 
2.6.2 Liver fibrosis 
Hepatic fibrosis describes an exuberant wound-healing response to chronic liver 
injury associated by hepatocellular damage, inflammation and continuous tissue 
remodelling (Bataller and Brenner, 2001). As a consequence excessive deposition 
and altered composition of extracellular matrix (ECM) proteins (mainly collagen 
types I, III and IV) in the liver parenchyma takes place, which in turn distorts the 
normal hepatic architecture leading to fibrous scars (Iredale, 2007). Therefore, 
advanced hepatic fibrosis is accompanied by portal hypertension within the liver. 
Hepatic stellate cells (HSC), first described by Kupffer, account for 5 -8 % of total 
cells in normal liver. HSC are regarded as central mediators of liver fibrosis 
because they are the major source of ECM proteins. They are located in the 
perisinusoidal space between the anti-luminal side of endothelial cells and the 
basolateral surface of hepatocytes with higher frequency in the periportal area 
than centrilobularly (Mann and Mann, 2009; Atzori et al., 2009). In normal liver, 
HSC are mainly in a quiescent state containing droplets of vitamin A in their 
cytoplasm. Quiescent HSC are involved in ECM homeostasis as they express 
metalloproteinases (MMPs) for ECM degradation and inhibitors of 
metalloproteinases (TIMPs) for ECM maintenance, respectively (Atzori et al., 
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2009). As response to various stimuli during liver injury, quiescent HSC undergo 
morphological changes associated with a loss of their vitamin A reservoir. This 
activation process is a hallmark of fibrogenesis (Friedman and Arthur, 1989). HSC 
transform into highly proliferative myofibroblast like cells (activated HSC) which 
express α smooth muscle actin (α sma), a histological marker for activated HSC in 
injured liver (Mann and Mann, 2009). Activated HSC migrate to and accumulate at 
the side of tissue repair. They overproduce ECM proteins (mainly collagen type I) 
and TIMPs (mainly TIMP-1) which in turn block matrix degradation by MMPs. 
Further, activated HSC up-regulate an array of cytokines (e.g. IL-6), chemokines 
(e.g. MCP-1), and mitogens (e.g. TGF-β and PDGF) which further activate HSC in 
an autocrine manner. Therefore, treatment approaches aim to reduce or inhibit 
either the proliferative or fibrogenic responses of HSC which would reduce the 
deleterious effects of HSC in the progression of hepatic fibrosis (Gäbele et al., 
2003). 
 
2.6.3 Liver cancer 
Liver cancer comprises all types of histologically distinct cancers within the liver. 
Most liver cancers are secondarily that means that these metastases arise from 
primary tumors in other organs. Primary liver cancer (its origin is within the liver) 
include hepatocellular carcinoma (HCC), intrahepatic bile duct carcinoma 
(cholangiocarcinoma), hepatoblastoma, bile duct cystadenocarcinoma, 
haemangiosarcoma and epitheliod haemangioendothelioma (Farazi and DePinho, 
2006).  
HCC is the most common type of primary liver cancer, representing about 80% of 
all cases (Farazi and DePinho, 2006). Furthermore, it is the fifth most frequent 
cancer worldwide and because of the lack of efficient therapies, the cancer with 
the third highest mortality after lung and colon cancer (Kubicka et al., 2000; 
Villanueva et al., 2007). HCC affects all segments of the world population, 
although geographical variations in the incidence occur due to the large 
heterogeneity of several risk factors within the population (Farazi and DePinho, 
2006; Bruix et al., 2004). The highest incidence of HCC is in most of the Asia-
Pacific regions as well as in Africa. However and importantly, the incidence is 
steadily increasing even in Western countries (Bruix et al., 2004). The most 
Introduction  22 
prominent risk factors are hepatotropic viruses with chronic hepatitis B and C viral 
infections, being the most relevant ones, respectively. Other main risk factors 
include chronic alcohol abuse, metabolic liver disease, aflatoxins, and virtually all 
cirrhosis-induced conditions (Farazi and DePinho, 2006). The molecular 
mechanisms which are responsible for the development and progression of HCC 
depend on responsible risk factors and are not well known. In general, 
hepatocarcinogenesis is a complex process which includes genetic and epigenetic 
changes that occur during initiation, promotion, and progression (Aravalli et al., 
2008). On the cellular level, increased expression of several factors which are 
responsible for cancerous cell survival were elucidated. Aberrant activation of the 
transcription factor NFκB as well as the MAP kinase/ERK pathway have been 
linked to initiation and progression of HCC since these pathways are known to 
protect cells from apoptosis (Arsura and Cavin, 2005; Ito et al., 1998).  
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2.7 Aim of the thesis 
The aim of this thesis was to analyze the effects of hop bitter acids on liver 
diseases with the focus on fibrosis and hepatocellular carcinoma. First, the effect 
of BA on hepatic stellate cell activation and their potential to inhibit molecular 
processes involved in the pathogenesis of hepatic fibrosis caused by activated 
HSC was examined. Second, the effect of BA on hepatocellular carcinoma (HCC) 
cells was assessed to unravel possible anti-tumorigenic effects. Finally, we 
prepared a BA-supplemented chow for oral application in rodents and performed 
recovery experiments to test the stability of BA in this chow. 
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3 Materials and Methods 
3.1 Chemicals and Reagents 
Anisaldehyde Sigma, Deisenhofen, Germany 
β-Mercaptoethanol Sigma, Deisenhofen, Germany 
Ciprobay Bayer, Leverkusen, Germany 
Collagenase type IV Sigma, Hamburg, Germany 
Cyclohexane Sigma, Hamburg, Germany 
Diflucan Pfizer, Karlsruhe, Germany 
DMEM medium high glucose PAA Laboratories, Pasching, Austria 
DMSO Sigma, Deisenhofen, Germany 
DNAse Qiagen, Hilden, Germany 
Ethyl acetate Sigma, Deisenhofen, Germany 
Fetal calf serum (FCS) PAN-Biotech, Aidenbach, Germany 
GIBCO medium Invitrogen, Carlsbad, USA 
Glacial acetic acid Sigma, Deisenhofen, Germany 
Hexane Sigma, Deisenhofen, Germany 
Hohentanner Hohentanner Brauerei, Hohentann, Germany 
Hop bitter acid extracts NATECO2, Wolnzach, Germany 
Hydrochloric acid Sigma, Deisenhofen, Germany 
Milk powder Carl Roth, Karlsruhe, Germany 
Nonidet® P40 Roche Diagnostics, Mannheim, Germany 
Paraformaldehyde Sigma, Deisenhofen, Germany 
PBS buffer PAA, Pasching, Austria 
Penicillin Invitrogen, Karlsruhe, Germany 
Petroleum ether Sigma, Deisenhofen, Germany 
Sodium dodecyl sulfate Roth, Karlsruhe, Germany 
Sodium hydroxide Roth, Karlsruhe, Germany 
Streptomycin Invitrogen, Karlsruhe, Germany 
Sulfuric acid Merck, Darmstadt, Germany 
TNF α R&D, Wiesbaden-Nordenstadt, Germany 
Triton X-100 Sigma, Deisenhofen, Germany 
Trypan blue solution Sigma, Deisenhofen, Germany 
Trypsin/EDTA PAA Laboratories, Cölbe, Germany 
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3.2 Laboratory expendables 
Cell culture flasks (various sizes) Corning, New York, USA 
CryoTube vials Nunc, Roskilde, Denmark 
Eppendorf tubes (1.5 and 2.0 ml) Eppendorf, Hamburg, Germany 
Falcon tubes (15- and 50 ml) Corning, New York, USA 
Glassware (various types) Schott, Mainz, Germany 
Multiwell plates (various sizes) Corning, New York, USA 
Neubauer hemocytometer Marienfeld GmbH, Lauda-Königshofen, Germany 
Pipet tips (various sizes) Eppendorf, Hamburg, Germany 
Pipettes (stripettes® various sizes) Corning, New York, USA 
Silica gel plates GF254 Merck, Darmstadt, Germany 
Strip tubes (0.2 ml) Peqlab, Erlangen , Germany 
 
3.3 Laboratory instruments 
Heating block: 
Thermomixer comfort  
 
Eppendorf, Hamburg, Germany 
PCR-cycler: 
GeneAmp® PCR System 9700 
 
Applied Biosystems, Foster City, USA 
Q-PCR-cycler: 
TaqMan® Abi Prism 7900 HT 
 
Applied Biosystems, Foster City, USA 
Laminar flow: 
Biosafety cabinet 
 
Hera Safe, Heraeus, Osterode, Germany 
Pipettes: 
Gilson (P2, P20, P200, P1000) 
 
Gilson, Bad Camberg, Germany 
Pipette controllers:  
Accu-jet® 
 
Brand, Wertheim, Germany 
Cell incubator: 
Binder series CB 
 
Binder, Tuttlingen, Germany 
Shaking devices: 
KS 260 Basic Orbital Shaker  
 
IKA® Werke, Staufen, Germany 
Power Supplies: 
Consort E145 
Power Supply-EPS 301 
 
Peqlab, Erlangen, Germany 
Amersham Biosiences, Munich, Germany 
Spectrophotometer: 
EMax® Microplate Reader 
 
MWG Biotech, Ebersberg, Germany 
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SPECTRAFluor Plus Tecan, Männedorf, Switzerland 
Scale: 
MC1 Laboratory LC 620 D 
 
Sartorius, Göttingen, Germany 
Water bath: 
Haake W13/C10 
 
Thermo Fisher Scientific, Karlsruhe, Germany 
Centrifuge: 
Biofuge fresco 
Megafuge 1.0 R  
 
Heraeus, Hanau , Germany 
Heraeus, Hanau, Germany 
Microscope: 
Olympus CKX41 
Zeiss Axioskop2 mot plus microscope
 
Olympus, Hamburg, Germany 
Zeiss, Göttingen, Germany 
UV/VIS spectrophotometer: 
NanoDrop® ND-1000  
 
Peqlab, Erlangen, Germany 
Cell freezing machine: 
Nicool LM 10 freezing machine 
 
Air Liquide, Düsseldorf, Germany 
Rotary evaporator: 
Laborota 4004-control 
 
Heidolph, Schwabach, Germany 
 
3.4 Cell culture 
3.4.1 Cell culture medium 
General cell culture medium DMEM (high glucose/300 µg/ml L-glutamine) 
supplemented with: 
10% (v/v) FCS  
400 U/ml  Penicillin  
50 µg/ml  Streptomycin 
 
HSC medium DMEM  
supplemented with: 
10 % (v/v) FCS  
10 µg/ml  Diflucan  
  4 µg/ml  Ciprobay  
Freezing medium 5 Vol  DMEM 
3 Vol  FCS 
2 Vol  DMSO 
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3.4.2 Cultivation of cells 
In general, all cell culture work was perfomed within a laminar flow biosafety 
cabinet (Hera Safe, Osterode, Germany) to avoid contaminations. Cells were 
cultivated at 37 °C in a humidified atmosphere of 10 % CO2 in air. The different cell 
types were cultured with the appropriate cell culture medium as listed in chapter 
3.4.1. For cell transfer adherent cells were washed with PBS and detached with 
trypsin (0.05 %)/EDTA (0.02 %) at 37 °C. The same volume of DMEM containing 
10% FCS was used to stop trypsin activity. Subsequently, cell suspension was 
transferred to a falcon tube and centrifuged at 500 G for 5 min. The obtained cell 
pellet was re-suspended in fresh culture medium and cell number was determined 
(see chapter 3.4.3). A cell density thinning factor of 5 to 10 was used when cells 
were reseeded to new cell culture flasks. Medium change took place every second 
day and cell transfer was repeated when cells reached about 80 % of confluence. 
Cell growth and morphology were microscopically monitored using an Olympus 
CKX41 microscope and ALTRA20 Soft Imaging System (Olympus, Hamburg, 
Germany). Accrued cell culture waste was autoclaved before disposal. 
 
3.4.3 Determination of cell number and viability 
To determine cell number and cell viability, cells were diluted 1:2 with trypan blue 
solution and transferred to a Neubauer hemocytometer. A blue staining of cells 
indicated their impaired cell membrane integrity. Intact cells on the other hand 
appear white and therefore can be distinguished. To determine total cell number, 
all four quadrants (each contains sixteen smaller squares) of the hemocytometer 
were counted and cell number was calculated with the following equation: 
 
Cell number/ml = Z x DF x 104 ÷ 4 
 Z = counted cell number in all four quadrants 
 DF = dilution factor (factor = 2) 
 
For determination of cell viability the ratio of living cells to total cell number was 
calculated. 
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3.4.4 Cryopreservation of cells 
For cryopreservation, 1 x 106 cells were transferred into cryotube vials and 
centrifuged at 500 G for 5 min. The supernatant was discarded, and the obtained 
cell pellet was re-suspended in 1 ml of freezing medium. Thereafter, cells were 
gently cooled down by a stepwise reduction of the temperature using a Nicool LM 
10 freezing machine and following program: 
 
Level 4:  30 min  
Level 8:  30 min  
Level 10:  30 min  
 
The frozen cell suspensions were then transferred to a liquid nitrogen storage tank 
for long-time cryopreservation. 
 
For cell thawing of cryopreserved cells, stocks were quickly defrosted in a water 
bath adjusted to 37 °C. Afterwards, defrosted cell suspension was mixed with 8 ml 
of warm DMEM and centrifuged at 300 G for 5 minutes. The obtained cell pellet 
was re-suspended in 10 ml of warm DMEM and transferred into a T25 cell culture 
flask. On the next day medium was exchanged. 
 
3.4.5 Human hepatocellular carcinoma cell lines 
The hepatocellular carcinoma cell lines HepG2 (ATCC HB-8065), PLC (ATCC 
CRL-8024), and Hep3B (ATCC HB-8064) were obtained from the American Type 
Culture Collection (ATCC). 
 
3.4.6 Isolation of primary human hepatic stellate cells 
Isolation of primary human hepatic stellate cells was done in cooperation with the 
Center for Liver Cell Research (Department of Surgery, University of Regensburg, 
Germany) using a two-step EGTA/collagenase perfusion procedure with little 
modifications (Amann et al., 2009; Hellerbrand et al., 1996; Thasler et al., 2003). 
Remnant liver samples were obtained from patients with informed consent after 
partial hepatectomy. Human tissue samples used for cell isolation were non-
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pathological, which was confirmed by macroscopical as well as microscopical 
analysis. Moreover, all liver resections have been negatively tested for HBV, HCV 
and HIV infection. In the first step, cell suspension was centrifuged at 80 G (8 min, 
4 °C) to remove parenchymal hepatocytes. The supernatant containing the non-
parenchymal cells was centrifuged again at 700 G for 7 min (4 °C). The cell pellet 
was re-suspended in HSC medium and seeded in T25 or T75 flasks. After 45 min 
flasks were tapped and medium was changed. Liver sinusoidal endothelial cells 
are not able to live under these conditions and die within the first 24 h. Medium 
change was done daily in the first week of cultivation. Thereafter, medium was 
changed every 2-3 days. In vitro activation of HSC can be observed within the first 
two weeks of cultivation on uncoated plastic surfaces. Activated HSC are highly 
proliferative and were split 1:3 after two weeks in culture. Hereby, HSC but not 
Kupffer cells detach, which was confirmed in previously done analyses (Mühlbauer 
et al., 2006) 
 
3.4.7 Isolation of primary murine hepatic stellate cells 
Isolation of primary hepatic stellate cells (HSC) was performed with 8 week old 
female BALB/c mice (Charles River Laboratories, Sulzfeld, Germany) using the 
two step collagenase method of Seglen with minor modifications (Seglen, 1976). 
Following buffers were used and always freshly prepared prior to use. 
 
Perfusion buffer:    DMEM  
      0.25 g/l EGTA (pH 7.3) 
 
Digestion buffer:    DMEM 
0.02 % Collagenase type IV (440 U/mg 
solid collagenase activity) 
      2.0 mM CaCl2 
 
First mice were set under deep ketamine/xylazine anesthetization according to the 
guidelines of the Central Animal Facility (ZTL) of the University of Regensburg 
(Germany). In general, 0.2 ml Xylazin 2 % (Serumwerk Bernburg AG, Bernburg, 
Germany) and 0.6 ml Ketamin 10 % (WDT, Garbsen, Germany) were mixed. 
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Thereafter, 25 g weighty mice were intraperitoneal injected 30 – 40 µl of this 
mixture. Both anaesthetics were obtained from the ZTL of the University of 
Regensburg. After correct anesthetization, an abdominal incision was performed 
beginning 1 – 2 cm away from the hind legs up to the sternum as shown in Figure 
3.1. Thereafter, two horizontal cuts were set to expose the liver. Special care must 
be taken not to induce diaphragmatic hernia.  
 
Figure 3.1 Anesthetized mouse with indicated cutting lines (A) and an open abdomen (B). 
 
Afterwards, the vena cava inferior (IVC) and portal vein were carefully ligated 
loosely with sterile threads as shown in Figure 3.2. 
 
Figure 3.2 (A) open abdomen with prepared ligations of the portal vein and vena cava inferior. 
(B) perfused liver with the catheder inserted in the portal vein. 
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In the next step, a 22 GA catheter (Optiva 2, Medex Medical, Klein-Winterheim, 
Germany) was implemented into the portal vein and fixed using the hitherto placed 
ligature. The catheter was connected to the perfusion system composed of an 
ISMATEC pump system (IDEX Health & Science GmbH, Wertheim-Mondfeld, 
Germany), flexible tubings (Novodirect, Kehl/Rhein, Germany) and a water bath 
adjusted to 37 °C used for buffer as well as exposed tubing warming. The flowrate 
was set to 4 ml/min. First, the liver was flushed for 5 min with perfusion buffer. 
Immediately after perfusion start, the IVC was cut behind the ligature to prevent 
liver from high pressures. To ensure an anterograde perfusion flow, the thorax was 
opened one minute after perfusion start, heart segmentation was performed and 
the IVC ligation was tightened. Thereafter, perfusion was implemented with 100 ml 
of digestion buffer (Figure 3.2 B). Afterwards, liver was separated and the 
gallbladder was removed. Perfused liver was washed in ice cold PBS, minced in 
ice cold DMEM and centrifuged at 80 G (8 min, 4 °C) to separate parenchymal 
cells (hepatocytes). Thereafter, the supernatant containing non-parenchymal cells 
was centrifuged at 500 G (5 min, 4°C). The pellet was suspended in HSC medium 
and seeded in T25 flasks. The procedure of further cultivation was the same as 
described for human HSC (see chapter 3.4.6). 
 
3.5 Hop bitter acid extracts 
Hop extracts were provided by NATECO2 GmbH. Two hop bitter acid extracts 
were used in the experiments. The first one called Herkules, contained 57.2 % 
(m/m) α-acids (humulone, cohumulone, adhumulone) and 18.3 % (m/m) β-acids 
(lupulone, colupulone, adhumulone) as determined by HPLC analysis. Therefore, 
this hop extract can be denoted as α-acid rich. The second extract called 
Strisselspalter is a β-acid rich extract. HPLC analysis revealed 13.0 % (m/m) α-
acids (humulone, cohumulone, adhumulone) and 51.9 % (m/m) β-acids (lupulone, 
colupulone, adhumulone). For experiments, a stock solution (100 mg/ml) was 
prepared by dissolving the extracts in DMSO. After a centrifugation step, unsolved 
compounds were removed and the stock solution was aliquoted and stored at 
−20 °C. Samples indicated as controls in the particular experiments received 
DMSO at the same concentration as BA treated samples. 
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3.6 Enrichment of hop bitter acids 
For further enrichment of bitter acids, 10 g hop extract was solved in 100 ml 
hexane. The obtained solution was transferred to a separating funnel and a 
quantitative liquid-liquid extraction was done with 100 ml sodium hydroxide (pH 
12). The sodium hydroxide solution (containing the deprotonated BA) was acidified 
with hydrochloric acid (37 %) followed by a quantitative liquid-liquid extraction with 
petroleum ether as second phase. Subsequently, purified BA as well as the 
fraction containing remnant lipophilic compounds (not soluble at pH 12) were dried 
using a rotary evaporator.  
Separation success of BA and remnant lipophilic compounds was checked by thin 
layer chromatography. Anisaldehyde spray reagent was used for visualization of 
remnant lipophilic compounds (Kritchevsky et al., 1963).  
 
3.7 Preparation of a hop bitter acid-supplemented chow 
for oral application 
The standard chow for mice and rats (Ssniff® R/M-H Cat # V1534-0) contains a 
balanced mixture of cereals, cereal byproducts, oilseed compounds, minerals, 
vegetable oils, vitamins and trace elements. In general, the chow is pressed to 
pellets. 
We already used this chow in combination with hop compounds as previously 
done with the hop chalcone xanthohumol (Dorn et al., 2010, 2012a; b). We 
provided the chow producing company Ssniff (Soest, Germany) with the BA-
extract "Herkules" (see chapter 3.5) to generate a chow with a final concentration 
of 1.75 % (m/m) of the BA-extract. In general, a typical mouse at 15 weeks of age 
weighs approximately 25 g and eats approximately 4 g a day. Therefore, the daily 
BA-intake is approximately 1.6 g/kg/bodyweight α-acids and 0.6 g/kg/bodyweight 
β-acids, respectively. This concentration was in the range used in previous studies 
in which BA had been administered to mice or men (Mannering et al., 1992; 
Farber et al., 1950). 
Additionally, we added 5 % (m/m) coconut oil and 1 % (m/m) lecithin to achieve 
complete homogeneity. Importantly, all transport and producing steps were 
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performed under cool (4 °C) and dark conditions. Moreover, the generated chow 
was set under vacuum to avoid oxidation reactions.  
 
3.8 Hop bitter acid-recovery from the hop bitter acid-
supplemented chow 
BA-recovery experiments (after storage of the chow at 4 °C or -20 °C for two 
month) were done by NATECO2 GmbH (Wolnzach, Germany) according to the 
EBC-Proceedings (Maastricht 1997, 223-230). The chow was ground and hop 
compounds were extracted with a mixture of methanol, ether and hydrochloric acid 
(12.5:62.5:25). After phase separation, the ether-phase containing the hop 
compounds was filtered through a 0.2 µm filter and analyzed via high pressure 
liquid chromatography (250 x 3.0 mm, ProntoSIL 120-C18-AQ, Bischoff, Leonberg, 
Germany). The elution was carried out with water/H3PO4 (100:0.5) (Phase A) and 
acetonitrile/H3PO4 (100:0.5) (Phase B) solutions. The following elution concept was 
used: from 55 % (A) and 45 % (B) to 0 % (A) and 100 % (B), respectively, in a 
timeframe of 34 min using a flowrate of 0.6ml/min. The whole elution process was 
recorded using a diode array detection system applying the following wavelengths: 
335 nm to detect all α- and β-acids, 270 nm to detect iso-α-acids and reduced iso-
α-acids. For absolute quantification different standards (Labor Veritas, Zürich, 
Swiss/Phytolab, Hamburg, Germany) were used. 
 
3.9 Thin layer chromatography  
Thin layer chromatography was used to monitor the enrichment success of hop 
bitter acids from the extract. Therefore, 1 % (w/v) dichlormethane solutions were 
made for samples of interest. These standardized solutions were afterwards 
spotted onto 0.3 mm thick GF254 silica gel plates. A solvent mixture of 
cyclohexane, ethyl acetate and glacial acetic acid (70:29:1, v/v) was used for 
separation under saturated conditions. Wavelengths of 256 nm, 330 nm, and 
daylight were used for visualization, respectively. The retention factor (Rf) of each 
sample was compared to known Rf values in the literature (Bauer et al., 2009).  
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3.10 RNA Analysis 
3.10.1 RNA Isolation 
RNA was used to analyze the state of transcription for genes of interest in cells 
stimulated with BA. For isolation of total RNA from cells, the RNeasy® mini Kit was 
used according to manufacturer’s instructions (Qiagen, Hilden, Germany). In 
general, all steps including RNA handling were prepared on ice using sterile 
plugged pipette tips. To avoid DNA contamination, a genomic DNA digestion step 
was performed using the RNase-free DNase set (Qiagen, Hilden, Germany). 
Afterwards, concentration of obtained RNA was determined with the NanoDrop® 
ND-1000 UV/VIS spectrophotometer (Peqlab, Erlangen, Germany). Ratios of 
260/280 and 260/230 were considered to verify purity and isolation success. 
Isolated RNA was subsequently used for reverse transcription PCR or stored at  
-80 °C.  
3.10.2 Reverse transcription PCR 
The reverse transcription PCR (RT-PCR) was used to synthesize stable 
complementary DNA (cDNA) from RNA. Total RNA was reverse transcribed into 
cDNA using the reverse transcription system (Promega, Mannheim, Germany). In 
general, the avian myeloblastosis virus reverse transcriptase enzyme (AMV) and 
random primers were used. A 25 µl reaction was prepared according to the 
following setup: 
 
4.9 µl nuclease free water 
4.0 µl MgCl2 (25mM) 
2.0 µl reverse transcription buffer (10x) 
2.0 µl dNTP mixture (10mM) 
1.0 µl random primers 
0.5 µl recombinant RNasin ® ribonuclease inhibitor 
0.6 µl AMV 
 
Afterwards 10 µl of 500 ng RNA/water mixture was added and the reaction was 
centrifuged briefly. Reverse transcription was performed at 42 °C for 30 min using 
a PCR cycler. Enzyme inactivation was achieved by a heat step at 95 °C for 5 
Materials and Methods  35 
minutes followed by a chill down to 4 °C. After addition of 75 µl nuclease free 
water, the generated cDNA was subsequently used for quantitative real time PCR 
or stored at -20 °C.  
 
3.10.3 Quantitative real time PCR 
Quantitative real time PCR (qRT-PCR) was used to quantify specific mRNA 
expression levels in the cells. It consists of a conventional polymerase chain 
reaction (PCR) with the addition of a fluorescence dye, e.g. SYBR® Green. Since 
SYBR® Green intercalates with double-strand DNA, this system offers the 
possibility to measure the PCR products after each cycle in real time. To quantify 
the expression level of a gene of interest, the expression of the housekeeper gene 
18S was also determined and used for normalization. In general, the ABI Prism® 
7900HT (Applied Biosystems, Foster City, USA) was used in combination with the 
QuantiFast SYBR Green PCR Kit (Qiagen, Hilden, Germany). For expression 
analysis, oligonucleotides from Sigma-Aldrich (Sigma, Deisenhofen, Germany) 
were used as listed in table 3.1. Expression of α-smooth muscle actin (α-sma), 
CCL-5 (RANTES) and keratinocyte growth factor (KGF) was analyzed applying the 
QuantiTect Primer assays (Qiagen, Hilden, Germany). A 10 µl reaction was 
prepared according to following setup:  
 
2.5 µl    H2Odest. 
0.25 µl   forward primer (20 µM)  
0.25 µl   reverse primer (20 µM)  
5 µl    QuantiFast® SYBR® Green PCR Master Mix 
2 µl     cDNA 
 
Following standard scheme has been used and adapted to the specific melting 
point temperature of each primer: 
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Initial denaturation:   95 °C, 900 s  
Three step PCR (40 cycles): 95 °C, 15 s 
     55-65 °C, 20 s 
     72 °C, 20 s 
Analysis of melting curve:  95 °C, 0 s 
     65 °C, 15 s 
     95 °C, 0 s 
     40 °C, 30 s 
 
Amplification products were validated using gel electrophoresis.  
 
Table 3.1 Set of primers used for quantitative RT-PCR analysis. 
 
3.11 Protein Analysis 
3.11.1 Isolation of whole cell proteins 
For whole cell protein extraction, cell culture medium was removed and cells were 
washed once with PBS. Thereafter, cells were lysed using an ice-cold cell lysis 
buffer (Cell signalling technology, Beverly, USA) according to manufacturer’s 
instructions. Afterwards, cells were scraped off with a cell scraper (Corning, 
NewYork, USA), transferred into 1.5 ml tubes and treated with an ultrasonoscope 
(Sonoplus hp 70, Bandelin electronics, Berlin, Germany) ten times for three 
seconds each round. After a centrifugation step at 20,000 G (10 min, 4 °C) the 
clear supernatant containing the proteins was subsequently used to determine the 
protein concentration as described in the next chapter. Thereafter, protein 
concentrations were adjusted, the solutions aliquoted and stored at -80 °C. 
 
gene Forward primer (5′–3′) Reverse primer (5′–3′) 
18S AAACGGCTACCACATCCAAG CCTCCAATGGATCCTCGTTA 
Col I CGGGCAGGACTTGGGTA CGGAATCTGAATGGTCTGACT 
MCP-1 TGGGCCTGCTGTTCACA TCCGATCCAGGTTTTTAATGTA 
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3.11.2 Determination of protein concentration 
The BCA protein assay kit (Pierce, Rockford, USA) was used for the determination 
of protein concentrations. In this assay Cu2+ is reduced to Cu1+ by present proteins 
under alkaline conditions leading to a blue-colored complex. Thereafter, the cation 
Cu1+ is detected by bicinchoninic acid (BCA) building a water soluble purple-
colored chelation-product. In general, 200 µl of alkaline BCA/copper(II) solution 
(50 parts of solution A mixed with 1 part of solution B) was added to 2 µl of protein 
solution using a 96-well plate and were incubated for 30 minutes up to one hour at 
room temperature. A wavelength of 562 nm and a spectrophotometer (EMax® 
Microplate Reader, MWG Biotech, Ebersberg, Germany) was used to measure the 
developed purple color. Protein concentration could be determined by doing a 
parallel quantification of a BSA standard.  
 
3.11.3 Western Blot Analysis 
3.11.3.1 SDS PAGE gel electrophoresis 
Following buffers and composition of gels were used: 
 
Laemmli buffer 62.5 mM Tris/HCl; pH 6.8 
2% (w/v) SDS 
10% (v/v) Glycerine 
5% (v/v) β-Mercaptoethanol 
 
Running buffer 25 mM Tris/HCl; pH 8.5 
200 mM Glycine 
0.1% (w/v) SDS 
 
Materials and Methods  38 
10% Resolving gel 7.9 ml  H2Odest. 
5.0 ml  1.5 M Tris/HCl; pH 8.8 
0.2 ml  10% (w/v) SDS 
6.7 ml  Acrylamide/Bisacrylamide 
  30%/0.8% (w/v) 
0.2 ml  Ammonium persulfate 
  10% (w/v) 
0.008 ml TEMED 
 
5% Stacking gel 2.7 ml  H2Odest. 
0.5 ml  1.0 M Tris/HCl; pH 6.8 
0.04 ml 10% (w/v) SDS 
0.67 ml Acrylamide/Bisacrylamide 
  (30%/0.8% w/v)  
0.04 ml Ammonium persulfate 
  10% (w/v) 
0.004 ml TEMED 
 
6.7 µl Laemmli buffer was added to 33.3 µl protein solution (standardized amount) 
and then heated at 95 °C for 5 min. After a short centrifugation step, the denatured 
proteins were applied on a SDS polyacrylamid gel which consists of a stacking gel 
and a running gel (detailed composition is listed above). Thereafter, the protein 
fractionation was separated by size in an electric field at 35 mA/150 V using the 
XCell SureLock™ Mini-Cell system (Invitrogen, Karlsruhe, Germany). The Full 
Range Rainbow Molecular Weight Marker (GE Healthcare, Freiburg, Germany) 
was used as size marker. 
 
3.11.3.2  Protein blot and detection 
Following buffer was used for the transfer: 
Transfer buffer 10% (v/v)  Methanol 
25 mM  Tris 
190 mM  Glycine 
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The successfully separated proteins were transferred electrophoretically (220 
mA/300 V for 1.5 h) from the gel to a nitrocellulose membrane (Invitrogen, 
Karlsruhe, Germany) using the XCell II Blot Module (Invitrogen, Karlsruhe, 
Germany). Afterwards, the membrane was tossed in PBS containing 5% milk 
powder for at least one hour at room temperature to block unspecific binding sites. 
Afterwards, the membrane was incubated with a specific primary antibody (listed 
in table 3.2) over night at 4 °C. The next day, the membrane was washed and then 
incubated with a secondary horseradish peroxidase (HRP) conjugated antibody 
(listed in table 3.2) for one hour at room temperature. Unbound antibody was 
removed by a washing step with PBS and the membrane was incubated with the 
ECL Plus Western Blotting Detection System solution (GE Healthcare, Freiburg, 
Germany) for one minute. In this system, HRP catalyzes the conversion of the 
acridan substrate Lumigen PS-3 to an acridinium ester intermediate which in turn 
reacts with peroxide under alkaline conditions. In the latter reaction light emits 
which was detected by autoradiography using a Biomax film (Kodak, Stuttgart, 
Germany) and a Curix 60 automatic film developer (Agfa, Cologne, Germany). The 
KS 260 Basic Orbital Shaker (IKA®; Staufen, Germany) was used for the 
incubation steps. 
 
Table 3.2  Used primary and secondary antibodies for western blot analysis. 
Primary antibody Manufacturer 
α−sma Santa Cruz, Heidelberg, Germany 
IκΒ−α Cell signalling, Beverly, USA 
phospho IκΒ−α Cell signalling, Beverly, USA 
JNK Cell signalling, Beverly, USA 
phospho-JNK Cell signalling, Beverly, USA 
β-actin Sigma, Deisenhofen, Germany 
Secondary antibody Manufacturer  
anti-mouse HRP Santa Cruz, Heidelberg, Germany 
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3.11.4 Immunocytochemistry 
The immunofluorescence staining allows the detection of tissue or cell specific 
proteins, respectively. The primary antibody is specific to the protein of interest. 
The second antibody which recognizes the first antibody is linked to a fluorophore. 
For immunofluorescence analysis, cells (5 x 104 cells per well) were seeded in 
permanox coated 4-well chamber slides (Thermo Fisher Scientific, Karlsruhe, 
Germany) and cultured overnight. The following day, cells were stimulated with BA 
for 14 h. For induction of NFκB activity 10 ng/ml TNF (R&D, Wiesbaden-
Nordenstadt, Germany) was added for additional 30 min. Subsequently, cells were 
washed with PBS and fixed using 4 % paraformaldehyd for five minutes. For 
permeabilization of cell membranes, 0.1 % Triton X-100 (Sigma-Aldrich, Munich, 
Germany) was added for 15 minutes. After two washing steps with PBS, a 
blocking solution (PBS and 5 % BSA, w/v) was added for 30 minutes. Thereafter, 
cells were incubated with a p65 antibody (Santa Cruz Biotechnology, Santa Cruz, 
USA) overnight at 4 °C. Next day, cells were washed three times with PBS, 
followed by incubation with the secondary antibody (Invitrogen, Carlsbad, USA) for 
1 h. After extensively washing steps, hard set mounting medium including DAPI 
(Vector Laboratories, Burlingame, USA) was added and images were collected by 
fluorescence microscopy using a Zeiss Axioskop2 mot plus microscope (Zeiss, 
Göttingen, Germany). 
 
3.11.5 Quantification of ERK 1/2 and NFκB 
Enzyme-linked immunosorbent assay (ELISA) was used to quantifiy phospho-
p44/42 and phospho-p65 levels, respectively. Here, we applied the PathScan 
phospho- sandwich ELISAs (Cell Signalling technology, Beverly, USA) according 
to manufacturer’s instructions. Here, a 96 well plate was coated with the specific 
capture antibody overnight. Thereafter, cell lysate was added to attach the 
endogenous p44 and p42 MAP Kinase (Erk1 and Erk2) or phospho-p65 protein to 
the capture antibodies. After that, captured proteins were linked to a specific 
detection antibody. Subsequently, this detection antibody was recognized by a 
horseradish peroxidase (HRP) conjugated antibody. For relative quantification a 
serial dilution of a strongly positive sample was used. For induction of NFκB 
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activity, cells were stimulated with conditioned medium from activated hepatic 
stellate cells. 
 
3.11.6 AP-1 reporter gene assay 
In the AP-1 reporter gene assay a plasmid was used which contains a luciferase 
reporter gene that is controlled by a transcription promoter which consists of seven 
repeats of the AP-1 element (TGACTAA). For transfection, HCC cells (2 x 105 cells 
per well) were seeded in six well plates (Corning, New York, USA) and transfected 
with 0.5 µg pAP-1 luc plasmid (Stratagene, La Jolla, USA) using Lipofectamin Plus 
reagent (Invitrogen, Karlsruhe, Germany) according to manufacturer’s instructions. 
For normalization of transfection efficiency, cells were co-transfected with 0.2 µg of 
pRL-TK plasmid resulting in a renilla luciferase acitivity (Promega, Mannheim, 
Germany). After 24 h, transfection-medium was removed and cells were 
stimulated with BA for 20 h. Subsequently, cells were lysed and the luciferase 
activities were measured using a luminometric assay (Promega, Mannheim, 
Germany). 
 
3.12 Analysis of cell culture supernatants 
All analysis were performed at the Department of Clinical Chemistry and 
Laboratory Medicine (University of Regensburg, Germany) using the Advia 1800 
analyzer (Siemens Healthcare Diagnostics, Eschborn, Germany). For 
determination of cytotoxic effects of BA, cells (4 x 105 cells per well) were seeded 
in 6 well plates (Corning, New York, USA) and grown overnight followed by 
stimulation with BA for another 24 h. Thereafter, supernatants were collected and 
centrifuged at 20,000 G for 5 min to remove detached cells and debris. The 
amount of lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) in 
the supernatants were used as marker for cell viability, respectively.  
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3.13 Functional assays 
3.13.1 Proliferation assay (XTT) 
To quantify cell proliferation, the colorimetric XTT kit (Roche Diagnostics, 
Mannheim, Germany) was used. This assay uses the tetrazolium salt XTT (2,3-
bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[phenylamino)carbonyl]-2H-tetrazolium hy-
droxide) which is reduced to the orange colored formazan by metabolic active 
cells. Formazan is released into the supernatant. Therefore, dye intensity can be 
directly read in the supernatant using a spectrophotometer at a wavelength of 
450 nm and a reference absorbance wavelength of 650 nm. The intensity directly 
correlates to the number of metabolically active cells. To analyze the effects of BA 
on cell proliferation, cells (4 x 103 cells per well) were seeded in 96 well plates 
(Corning, New York, USA) overnight. Thereafter, serum starvation was done for  
12 hto achieve cell cycle synchronization. Afterwards, cells were set back to 10 % 
FCS and stimulated with different concentrations of BA for 24 h and the 
colorimetric XTT assay was used (Roche Diagnostics, Mannheim, Germany) 
according to the manufacturer's instructions. Wavelengths of 450 nm and 650 nm 
were analyzed using the E max ELISA reader (Molecular Devices, Biberach an der 
Riss, Germany). 
 
3.13.2 Migration assay 
The Cultrex 96 Well Cell Migration Assay (Trevigen, Gaithersburg, USA) was used 
to quantify the migratory capacity. In general, this assay provides two 
compartments which are separated by a microporous membrane. Cells are 
seeded in the upper compartment and are allowed to migrate through the pores 
forced by chemotactic stimuli located in the lower compartment. After an 
appropriate cell migration time, migrated cells are carefully detached from the 
basal side of the membrane and quantified using calcein acetoxymethylester 
(calcein AM). This Calcein AM is absorbed by the cells, and cleaved to generate 
free calcein, which in turn can be detected fluorometrically. 
For quantification of migratory capacity, cells (0.4 x 105 cells/well) were seeded 
into the upper compartment of the provided 96-well plate. Importantly, only the 
lower compartment contained 10 % FCS as chemoattractant. After incubation at 
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37 °C for 8 h cell migration was quantified by fluorimetry using a SPECTRAFluor 
Plus microplate reader (Tecan, Männedorf, Switzerland). 
 
3.14 Statistical analysis 
Values are presented as mean ± SEM. Comparison between groups was made 
using the Student's unpaired t-test. A p value < 0.05 was considered statistically 
significant. All calculations were performed using the statistical computer package 
GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, 
USA). 
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4 Results 
As described in the introduction hop bitter acids (BA) exhibit multiple beneficial 
biological properties (see chapter 2.3), however, no data are available at present 
which describe effects on liver cells or liver diseases, respectively. The aim of this 
thesis was to address this issue. 
 
In particular, the focus was placed on three aspects:  
4.1 Effects of hop bitter acids on hepatic stellate cells as central mediators of liver 
fibrosis 
4.2 Effects of hop bitter acids on the tumorigenicity of hepatocellular carcinoma 
cells 
4.3 BA-recovery experiments from rodent chow supplemented BA-extract 
 
4.1 Effects of hop bitter acids on hepatic stellate cells  
4.1.1 Rationale 
Liver fibrosis can be regarded as a chronic wound healing process, which in most 
cases occurs on the ground of chronic liver inflammation; if left untreated liver 
cirrhosis develops, finally leading to liver failure. Therefore, up until now liver 
fibrosis represents a major medical problem with significant morbidity and mortality 
worldwide (Gäbele et al., 2003). 
Importantly, current evidence indicates that liver fibrosis is dynamic and can be 
bidirectional involving phases of progression and regression (Arthur, 2000). 
Moreover, only advanced fibrosis and cirrhosis are considered to be irreversible 
(Iredale et al., 1998). Thus, the development of anti-fibrotic drugs is a very 
attractive strategy to stem against chronic liver diseases. 
Here, we analyzed the anti-fibrotic capability of BA (β-rich extract) on hepatic 
stellate cells as central mediators of liver fibrosis. 
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4.1.2 In vitro activation of HSC 
The activation of HSC is accompanied by central pathophysiological changes in 
the liver and therefore can be regarded as hallmark of liver fibrogenesis (Bataller 
and Brenner, 2001; Friedman and Arthur, 1989). Our first goal therefore was to 
analyze the effect of BA on the early onset of activation of murine HSC. In vitro 
activation was achieved by culturing isolated HSC on uncoated plastic surfaces. 
Two days after isolation, quiescent HSC were exposed to BA at two different 
doses (2.5 and 5 µg/ml) for three days. Here, and in subsequent experiments, 
samples indicated as controls received DMSO at the same concentration as used 
as solvent for BA. No signs of cell toxicity were microscopically observed after 
incubation with DMSO and BA, respectively (Figure 4.1).  
 
 
 
Figure 4.1 Representative phase-contrast images of cultured HSC after 72 h incubation with 
the indicated concentrations of BA. Bar represents 200 μm in size. 
 
To identify the influence of BA on HSC activation, mRNA expression of two 
established markers of HSC activation, namely collagen type I (col I) and α-
smooth muscle actin (α-sma), was determined by quantitative RT-PCR analysis. 
Treatment with BA reduced the expression of collagen type I and α-smooth 
muscle actin compared to control HSC (Figure 4.2). 
 
 
Figure 4.2 Collagen type I and α-sma mRNA expression in HSC after 72 h incubation with 
indicated concentrations of BA was analyzed by qRT-PCR analysis. *p<0.05 compared to control. 
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Reduction of α-sma expression was also confirmed on the protein level by 
Western blot analysis (Figure 4.3).  
 
 
Figure 4.3 Western blot analysis of α-sma expression in HSC cells after 72 h incubation with 
indicated concentrations of BA. 
 
4.1.3 Proliferation and cell viability 
Once they are activated HSC exhibit a high proliferation rate, a mechanism that 
plays a key role in the progression of liver fibrosis since activated HSC are the 
main source of ECM deposition (Bataller and Brenner, 2001; Friedman and Arthur, 
1989). Thus, we assessed the effect of different BA concentrations on the 
proliferation of activated human HSC in vitro. Incubation with 5, 10 and 25 µg/ml of 
BA, respectively, led to a dose dependent inhibition of cell growth whereas 
proliferative activity was completely inhibited at a concentration of 25 µg/ml of BA 
(Figure 4.4).  
 
 
 
Figure 4.4 Effect of BA on the proliferation of activated HSC after 24 h stimulation. *p<0.05 
compared to control. 
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Microscopical analysis revealed first signs of cell bubbling of activated HSC 
stimulated with 25 µg/ml of BA, and incubation with 50 µg/ml of BA led to a 
complete detachment of HSC after 24 h (Figure 4.5). 
 
 
 
Figure 4.5 Phase-contrast images of activated HSC after 24 h incubation with the indicated 
concentrations of BA. Bar represents 200 μm in size. 
 
In line with these data, LDH concentration in the supernatant of HSC treated with 
BA up to a concentration of 10 µg/ml differed only slightly from control cells, while 
LDH levels were markedly increased upon incubation with BA at a concentration of 
25 µg/ml for 24 h (Figure 4.6).  
 
 
 
Figure 4.6 Twenty-four hours after stimulation with BA, the amount of lactate dehydrogenase 
(LDH) in the supernatants of activated HSC was measured as marker for cell membrane integrity. 
*p<0.05 compared to control. 
 
These analyses have been performed with a supercritical carbon dioxide hop bitter 
acid extract. To confirm that BA and not remnant hop compounds in the extract 
account for the observed effects, we separated BA from the extract by liquid-liquid 
extraction. Figure 4.7 depicts a thin layer chromatogram of the purified BA and the 
residual lipophilic compounds.  
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Figure 4.7 Thin layer chromatogram for hop bitter acid extract (BA), remnant lipophilic 
compounds (rLC) and purified bitter acids (p-BA). At a wavelength of 254 nm separation of main 
compounds was visualized. A wavelength of 366 nm was chosen for detection of brown fluorescent 
humulones with a retardation factor (Rf) of 0.3 and the blue fluorescent lupulones with Rf =0.58, 
respectively. Remnant lipophilic compounds were visualized by detection with anisaldehyde spray 
reagent (purple). 
 
A subsequent proliferation assay revealed that purified BA have the same anti-
proliferative potential as the hop extract, while the residual lipophilic compounds 
did not affect HSC proliferation (Figure 4.8).  
 
 
 
Figure 4.8 Effect of purified BA (p-BA) and remnant lipophilic compound (rLC) on the 
proliferation of activated HSC after 24 h stimulation. p-BA and rLC were applied in corresponding 
concentrations as present in stimulation experiments with the crude hop extract. *p<0.05 compared 
to control. 
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4.1.4 NFκB activity and pro-inflammatory gene expression 
Recent studies identified NFκB as one target of the anti-inflammatory effects of BA 
(Lee et al., 2007; Van Cleemput et al., 2009b). It has been shown that activation of 
the transcription factor NFκB plays a critical role in HSC activation (Hellerbrand et 
al., 1998b; a; Elsharkawy et al., 2005). Moreover, increased hepatic NFκB activity 
and responsiveness during activation of HSC is known to promote and perpetuate 
hepatic inflammation (Lee et al., 1995; Hellerbrand et al., 1998a; Lang et al., 
2000).  
Here, we found that 10 µg/ml BA repressed basal NFκB activity in activated HSC. 
In contrast, activation of c-Jun N-terminal kinase (JNK) was not impaired, 
indicating the specificity of the BA-mediated effects on the NFκB pathway (Figure 
4.9). 
 
Figure 4.9 Analysis of phospho-IκB-α and phospho-JNK protein levels in BA treated HSC 
compared to control cells by Western blotting. 
 
In accordance, immunofluorescence staining revealed that BA inhibit nuclear 
translocation of p65 in TNF stimulated activated HSC (Figure 4.10).  
 
Figure 4.10 Immunofluorescence analysis of TNF induced p65 localization in HSC pre-treated 
with BA.  
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In line with these findings, incubation with 10 µg/ml BA reduced gene expression 
of monocyte chemotactic protein-1 (MCP-1) and CCL-5 (RANTES) in activated 
HSC. Both pro-inflammatory chemokines are de novo expressed during HSC 
activation and are highly regulated via activation of the transcription factor NFκB in 
activated HSC (Hellerbrand et al., 1998b). In contrast, the keratinocyte growth 
factor (KGF) expression was not altered by BA. Also KGF is de novo expressed 
during HSC activation (Steiling et al., 2004) but its expression is not regulated by 
NFκB (Figure 4.11). 
 
 
 
Figure 4.11 Analysis of mRNA levels of MCP-1, CCL-5 and KGF expression in BA treated and 
control HSC by quantitative RT-PCR. *p<0.05 compared to control. 
 
4.1.5 Summary 
BA inhibit the in vitro activation process of freshly isolated HSC as evidenced by 
delayed expression of collagen I and α-sma mRNA and protein. Further, BA led to 
a dose dependent inhibition of cell proliferation and induced cell death in activated 
HSC. Already at lower concentrations BA inhibited IκB-α-phosphorylation, nuclear 
p65 translocation and binding activity in a dose dependent way (up to 10 µg/ml) 
with no effects on the JNK pathway. Accordingly, the same BA-doses inhibited the 
expression of pro-inflammatory and NFκB regulated genes as MCP-1 and 
RANTES, but did not affect expression of genes not related to NFκB signaling. 
Together, these findings indicate that BA inhibit NFκB activation, and herewith, the 
activation and development of the pro-fibrogenic phenotype of HSC. Thus, hop 
bitter acids appear as potential functional nutrient for the prevention or treatment 
of hepatic fibrosis. 
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4.2  Effects of hop bitter acids on hepatocellular carcinoma cells 
4.2.1 Rationale 
As already mentioned in Chapter 2.6.3 HCC has the third highest mortality due to 
inconspicuous symptoms in early stages as well as insufficient disease-specific 
diagnosis. Until now, surgical resection or transplantation is still the most 
promising treatment option of HCC. However, there is a high rate of disease 
recurrence because most patients are diagnosed at an advanced stage. In 
addition it has to be considered that the tumor develops in diseased liver with a 
variable degree of function derangement (Bruix et al., 2004). Thus, new 
therapeutic treatment options are highly needed. Hop bitter acids have gained 
considerable attention as chemopreventive agents but no data concerning the 
anti-tumorigenic effects of BA on HCC are available. Here, we analyzed the effect 
of BA on the tumorigenicity of HCC. 
 
4.2.2 Cell viability 
Our first aim was to define the effective dose range of BA on different human HCC 
cell lines. Cells were incubated with indicated concentrations of an α-acid rich (αE) 
and a β-acid rich extract (βE) for 24 h. Microscopic analysis revealed no 
alterations in BA treated HepG2, Hep3B and PLC cells up to a concentration of 
10 µg/ml. Higher concentrations led to first morphological changes, and a 
concentration of 50 µg/ml caused cell bubbling in all three HCC cell lines (Figure 
4.12).  
Results  52 
 
 
Figure 4.12  Representative phase-contrast images of (A) HepG2, (B) Hep3B and (C) PLC 
cells after 24 h incubation with the indicated concentrations of an α-acid rich (αE) and a β-acid rich 
extract (βE), respectively . Bar represent 200 µm in size. 
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In line with these data, aspartate aminotransferase (AST) concentration in the 
supernatant of HepG2 cells treated with the two hop extracts did only slightly differ 
from control cells up to a concentration of 25 µg/ml, while AST levels were 
markedly increased upon incubation with concentrations of 50 µg/ml indicating cell 
injury (Figure 4.13). Interestingly, β-extract showed more pronounced effects than 
α-extract regarding morphological changes and induction of AST release.  
 
 
 
Figure 4.13 After 24 h stimulation, the amount of aspartate aminotransferase (AST) in the 
supernatants of HepG2 cells treated with (A) an α-acid rich extract (αE) and (B) a β-acid rich 
extract (βE) was measured as biomarker for cell injury. *p<0.05 compared to control. 
 
4.2.3 Proliferation and migratory potential 
Acquisition of a highly proliferative and invasive phenotype is a main characteristic 
of tumor cells. Therefore, we investigated the effect of the two hop extracts on cell 
cycle synchronized HepG2 cells. Incubation with 15 µg/ml β-extract for 24 h led to 
a significant inhibition of the proliferation rate whereas a concentration of 25 µg/ml 
α-extract was required to achieve an anti-proliferative effect on HCC cells (Figure 
4.14).  
 
 
Results  54 
 
Figure 4.14 Effect of an α-rich (αE) and a β−rich (βE) hop extract on the proliferation of HepG2 
cells after 24 h stimulation. *p<0.05 compared to control. 
 
Next, we analyzed the effect of the hop extracts on the migratory capacity of HCC 
cells. Here, we applied a low concentration of BA-extracts (5 µg/ml) to exclude 
interfering effects on cell viability and proliferation, respectively. At this 
concentration both α- and β-extract exhibited a similar inhibitory effect on HepG2 
cell migration (Figure 4.15). 
 
 
 
Figure 4.15 Quantification of the migratory capacity of HepG2 cells incubated with 5 µg/ml of 
an α-rich (αE) and a β-rich (βE) hop extract compared to untreated control cells. *p<0.05 compared 
to control. 
4.2.4 ERK1/2, AP-1 and NFκB activity 
To get an insight into the molecular mechanism by which BA affect proliferation 
and migration of HCC cells, we analyzed different pathways which are known to 
affect HCC progression. Extracellular signal-regulated kinase (ERK1/2) is often 
deregulated in HCC, and its induction correlates with poor prognosis of HCC 
patients (Ito et al., 1998; Schmitz et al., 2008; Tsuboi et al., 2004). Stimulation with 
5 µg/ml of both hop extracts significantly reduced the amount of phosphorylated 
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ERK1/2 in HepG2 cells (Figure 4.16). Interestingly, the inhibitory effect of β-extract 
was more potent compared to α-extract.  
 
 
Figure 4.16 Quantification of phospho-ERK1/2 after 24 h stimulation with 5 µg/ml of an α-rich 
(αE) or a β-rich (βE) hop extract compared to untreated control cells applying the ELISA technique. 
*p<0.05 compared to control. 
 
Once activated, ERK1/2 pathway induces different transcription factors including 
the activator protein-1 (AP-1) (Ito et al., 1998). Therefore, we next applied a 
reporter gene assay to assess AP-1 activity in HepG2 cells stimulated with the two 
hop extracts. Both of them markedly inhibited AP-1 activity in HepG2 cells (Figure 
4.17).  
 
 
 
Figure 4.17 AP-1 activity after treatment with 5 µg/ml of an α-rich (αE) and a β-rich (βE) hop 
extract for 20 h using a reporter gene assay. *p<0.05 compared to control. 
 
Moreover, ERK-activation can also directly affect the transcription factor NFκB 
(Nakano et al., 1998; Zhao and Lee, 1999), and it has been shown that NFκB 
plays an important role in HCC progression (Amann et al., 2009; Arsura and 
Cavin, 2005; Pikarsky et al., 2004). Therefore the influence of BA on NFκB activity 
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was investigated. Both hop extracts significantly attenuated basal NFκB activity at 
a concentration as low as 5 µg/ml (Figure 4.18).  
 
 
 
Figure 4.18 Quantification of the basal NFκB activity in HepG2 cells which were incubated with 
5 µg/ml of an α-rich (αE) and a β-rich (βE) hop extract for 16 h. *p<0.05 compared to control. 
 
Further, the effect of both hop extracts on induced NFκB activity was assessed. To 
induce NFκB activation, HepG2 cells were stimulated with conditioned medium 
from activated hepatic stellate cells (HSC). Activated HSC secrete a variety of pro-
inflammatory cytokines, and previously, the influence of HSC on tumor 
aggressiveness has been demonstrated (Amann et al., 2009). Importantly, both 
hop extracts significantly alleviated HSC induced NFκB activity at concentrations 
as low as 5 µg/ml (Figure 4.19). 
 
 
 
Figure 4.19 Quantification of induced NFκB activity caused by conditioned medium from 
activated HSC after pretreatment with an α-rich (αE) and a β-rich (βE) hop extract for 16 h. *p<0.05 
compared to control. 
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4.2.5 Comparison of bitter acids and remnant lipophilic compounds 
Finally, we wanted to analyze whether concomitant compounds present in the α- 
and β-extracts contribute to the observed anti-tumorigenic effects on HCC cells. 
We separated BA from the β-extract by liquid-liquid extraction. Separation success 
was checked by thin layer chromatography (see Figure 4.7). Afterwards, HepG2 
cells were stimulated with the obtained purified bitter acids (pBA) and the remnant 
lipophilic compounds (rLC) at equimolar concentrations. Importantly, treatment 
with p-BA revealed the same anti-proliferative effect as the original β-extract 
whereas treatment with the remnant lipophilic compounds alone had no influence 
on proliferation (Figure 4.20). These findings confirmed that BA and not remnant 
hop compounds in the extracts account for the observed effects on HCC cells. 
 
 
Figure 4.20 Effect of purified bitter acids (p-BA) (A) and remnant lipophilic compounds (rLC) (B) 
on the proliferation of HepG2 applying the colorimetric XTT assay. p-BA and rLC were applied in 
corresponding concentrations as present in stimulation experiments with the original β-bitter acid 
extract. *p<0.05 compared to control. 
 
4.2.6 Summary 
Hop bitter acid extracts induced cell death in HCC cells at a concentration of 
50 µg/ml. Already at lower concentrations (5 – 25 µg/ml) both extracts led to a 
dose dependent inhibition of proliferation, and migration was suppressed at a 
concentration as low as 5 µg/ml. Analysis of different signaling pathways revealed 
an inhibition of ERK1/2 phosphorylation, down-regulation of AP-1 activity and an 
alleviation of NFκB activity in HCC cells by incubation with 5 µg/ml of either of both 
extracts. The β-acid rich extract showed more pronounced effects in all 
experiments. In summary, ERK1/2, AP-1 and NFκB, which are important factors in 
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tumor development and progression, were identified as targets of hop BA. These 
data suggest the potential use of BA as functional nutrients for both prevention 
and treatment of HCC. 
 
4.3 BA-recovery experiments from rodent chow supplemented 
BA-extract 
In vivo studies are desirable to verify the anti-fibrotic and anti-tumorigenic effects 
of BA seen in vitro. For this reason, we generated a chow for mice and rats 
supplemented with 1.75°% (m/m) of the standardized hop extract “Herkules”. This 
concentration is equivalent to 1 % (m/m) of (total) α-acids. A typical mouse at 15 
weeks of age weighs approximately 25 g and eats approximately 4 g a day. Thus, 
the concentration of BA can be translated to approximately 1.6 g/kg/bodyweight α-
acids and 0.6 g/kg/bodyweight β-acids, respectively.  
Since it is known that BA are very sensitive to oxidation and degradation, we tried 
to minimize these reactions during the whole process of chow production and 
storage. After production, the BA-chow was either stored at 4 °C or at -20 °C over 
a period of two month to mimic feasible storage conditions for in vivo application. 
Afterwards, the composition of BA in the chow was analyzed using the HPLC-
Diode Array Detection system in collaboration with NATECO2 GmbH (Wolnzach, 
Germany). 
After 2 month of storage at -20 °C, analysis of the chow revealed 0.39, 0.27 and 
0.091 % (m/m) for the three main analogues of α-acids (n-,co-,ad-) and 0.062, 
0.105 and 0.018 % (m/m) for the three main analogues of β-acids (n-,co-,ad-), 
respectively (table 4.1). Further, 0.01 % (m/m) of pre-humulone derivatives was 
detected. The recovery was approximately 75 % for genuine α-acids and 
approximately 58 % for genuine β-acids. The amount of degradation products was 
0.037 % (m/m) for humulinic acid derivatives, the main α-acids degradation 
product, and 0.048 % (m/m) for hulupones, the main β-acids degradation product, 
respectively.  
Next, we assessed the chow stored at 4 °C for 2 month. Here, we detected a 
much more pronounced decrease of the three main analogues of α-acids (n-,co-, 
ad-) to 0.044, 0.033, and 0.01 % (m/m), respectively (table 4.1). Similarly, the 
three main analogues of β-acids (n-,co-,ad-) dropped significantly to 0.004, 0.007 
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and 0.001 % (m/m), respectively. Pre-humulone derivatives were not detectable 
any more, whereas the humulinic acid derivatives and hulupones as main α- and 
β-acid degradation products, respectively, increased to 0.047 % (m/m) and 
0.085 % (m/m). In summary, the recovery of genuine α-acids dropped to 9 % and 
approximately 4 % for genuine β-acids, respectively, after a 2 month storage 
interval at 4 °C. 
These findings indicate a stronger decay of BA during storage at 4 °C compared to 
-20°C. Recovery of genuine α- and β-acids significantly dropped from 75 % and 
58%, when stored at -20 °C, to 9 % and 4 % when stored at 4 °C, respectively 
(table 4.2). The detailed composition of BA in the chow stored at 4 °C or at -20 °C 
is listed in table 4.1. Concentration and recovery of total BA is shown in table 4.2 
 
Table 4.1 Comparison of BA and BA-degradation products in chow supplemented with the 
BA-extract Herkules stored at 4 °C or -20 °C. 
 
Compound [% m/m] storage at 4 °C  storage at -20 °C  
n-humulone 0.044 0.39 
co-humulone 0.033 0.27 
ad-humulone 0.01 0.091 
pre-humulone-derivatives n.d. 0.01 
n-lupulone 0.004 0.062 
co-lupulone 0.007 0.105 
ad-lupulone 0.001 0.018 
humulinic acid-derivatives 0.047 0.037 
hulupones 0.085 0.048 
co-isohumulone n.d. n.d. 
n-isohumulone n.d. n.d. 
ad-isohumulone n.d. n.d. 
(n.d. = not detectable) 
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Table 4.2 Concentration and recovery of total BA in chow supplemented with BA-extract 
Herkules stored at 4 °C or -20 °C. 
 
Compounds 4 °C 
[% m/m] 
recovery at 
4 °C [%] 
-20 °C 
[% m/m] 
recovery at 
-20 °C [%] 
Σ α-acids (co-, n-, -ad) 0.09 9 0.75 75 
Σ β-acids (co-, n-, -ad) 0.012 4 0.185 58 
Σ iso-α-acids  n.d. - n.d. - 
(n.d. = not detectable) 
 
In vivo application of BA is a desirable step to unravel the mechanisms of action of 
BA. However, since BA are very sensitive to oxidation and degradation it is 
essential that the individual composition of BA during the application is well 
controlled. Furthermore, optimal storage conditions are required to diminish 
potential ill-defined oxidation and degradation products. Together, our data clearly 
show that degradation and oxidation processes occur even under cooled storage 
conditions, at least in the present chow and the used BA-extract, respectively. 
Based on these data we decided not to proceed to analyse the effect of this BA-
supplemented chow in rodent models of fibrosis or hepatocellular cancer. 
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5 Discussion 
Hop bitter acids (BA) are multipotent bioactive compounds (see chapter 2.3), 
however, no data concerning the effects on liver cells or liver diseases, 
respectively, are available at present. Therefore, the aim of this thesis was to 
address this issue. In particular, we analyzed the effects of BA on hepatic stellate 
cells as central mediators in hepatic fibrosis (see chapter 4.1) as well as BA 
effects on hepatocellular carcinoma cells (see chapter 4.2).  
 
In the following, the discussion is divided into three main chapters in accordance 
to the arrangement of the results in chapter 4: 
 
5.1 Hop bitter acids and hepatic stellate cells 
5.2 Hop bitter acids and hepatocellular carcinoma 
5.3. Poor recovery of hop bitter acids in animal chow supplemented with a bitter 
acid-extract 
 
5.1 Hop bitter acids and hepatic inflammation and fibrosis 
In the present study we aimed to analyze the effects of hop bitter acids (BA) on 
hepatic stellate cells (HSC). The activation of these cells in response to liver injury 
is considered as the key event of hepatic fibrosis (Bataller and Brenner, 2001). 
Activated HSC are the cellular source of the excessive deposition of extracellular 
matrix during chronic liver injury (Mann and Mann, 2009). Further, the activation 
process of HSC is paralleled by de novo expression of several cytokines and 
chemokines, and by this, activated HSC also significantly contribute to hepatic 
inflammation and perpetuation of fibrosis. 
Noteworthy, BA exhibited a profound effect on several pathophysiological 
characteristics of HSC in vitro. The activation of HSC was significantly inhibited at 
BA concentrations of 2.5 µg/ml and 5 µg/ml. In a similar dose range, BA also 
reduced proliferation of activated HSC and their expression of the pro-
inflammatory chemokines MCP-1 and RANTES. Both chemokines are regulated 
by NFκB and increased levels are associated with fibrosis progression in chronic 
liver disease (Jarrar et al., 2008; Wouters et al., 2008). Further, NFκB activation is 
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a central pathophysiological mechanism during HSC activation (Hellerbrand et al., 
1998a; b; Elsharkawy et al., 2005). Importantly, our study revealed that BA inhibit 
NFκB activity in activated HSC in vitro. In contrast, neither activation of JNK nor 
the expression of genes not related to NFκB activity were affected, which confirms 
that the observed effects are specific for the NFκB pathway and are not related to 
(unspecific) cytotoxic effects.  
In this study we applied a hop extract enriched for bitter acids, which harbored the 
possibility that remnant hop compounds contribute to the anti-fibrogenic effects in 
addition to BA. However, we separated BA from the extract by liquid-liquid 
extraction and observed a striking similarity between the anti-fibrogenic effects of 
these purified BA and the original extract. In contrast, residual lipophilic 
compounds did not exhibit any effects on HSC. Together, these findings strongly 
suggest that indeed BA exclusively account for the observed effects on HSC.  
Little is known about the metabolism and bioavailability of BA. In one study by 
Desai et al. after a single oral uptake of 940 mg of isomerized α-acids (called 
META060) serum concentrations of 4-15 µg/ml were detected in men with the 
highest concentrations between 2 and 4 hours after intake (Desai et al., 2009). 
Although according analysis are missing, it can be expected based on the 
anatomical situation that after oral intake BA concentration is significantly higher in 
the portal vein than in systemic circulation. Further, it has to be considered that 
HSC are located in the liver in the space of Disse (or perisinusoidal space) i.e. 
between the sinusoid and the hepatocytes. Herewith, HSC are directly exposed to 
the BA concentration reaching the liver via the portal vein irrespective of 
(subsequent) metabolisms in hepatocytes. Thus, it can be speculated that the 
dose range of 5-10 µg/ml shown to reveal anti-fibrogenic effects on HSC in vitro, 
can be achieved with significantly lower oral doses of BA than used in the study of 
Desai and colleagues (Desai et al., 2009). 
Still it has to be noted, that there are substantial variations of used BA, extraction 
methods as well as analysis of the composition in the literature (Van Cleemput et 
al., 2009a). Therefore, it is hard to compare our observations with other 
experiments. However, most of the observed effects of BA on liver cells (5-
10 µg/ml) were in a dose range that was also observed as effective in other 
studies using similar hop extracts and other cell lines. 
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Beer is the major dietary source of BA, but the average content of BA in beer is 
probably not high enough to produce a (hepato)protective effect in humans. Thus, 
Foster et al. revealed that the amount and composition of BA strongly varies in 35 
different sorts of beers (Foster et al., 2009). Furthermore, there is certainly 
unanimous hesitancy among researchers to recommend drinking alcohol to avoid 
any kind of disease because of the fine line between moderate and binge drinking. 
Certainly, this is even truer in the case of chronic liver disease. However, different 
methods (i.e. using liquid supercritical carbon dioxide) were developed to isolate 
BA from hop cones in large quantities and thus, independent of beer intake BA 
may be used as hepatoprotective dietary supplement.  
Still, caution has to be taken and more research is needed before it is known 
whether the findings of the present study can be applied to humans. Importantly, 
we found that BA exhibit their anti-fibrogenic effects on both primary murine and 
human HSC, and a safety study by Farber et al. did not reveal toxic effects on 
liver, kidney, bone marrow or myocardium in man after oral application of BA at a 
concentration of 5.0 g per day for three months (Farber et al., 1950). Furthermore, 
recent reports indicate that BA have a positive effect on lipid metabolism, glucose 
tolerance and insulin resistance in animals (Yajima et al., 2004; Miura et al., 2005; 
Yajima et al., 2005). Still, further safety studies as well as efficacy studies in 
experimental in vivo models of hepatic fibrosis are required. However, the present 
study indicates the potential of BA as functional nutrient to ameliorate inflammation 
and fibrosis in chronic liver disease. 
 
5.2 Hop bitter acids and hepatocellular carcinoma 
In the second part this thesis aimed to analyze the effects of bitter acids (BA) on 
tumorigenicity of HCC cells. To get a first insight in differential effects of α-BA and 
β-BA we used hop extracts enriched with either one of these two related series 
and found that both extracts exhibited a profound effect on ERK1/2 as well as on 
AP-1 and NFκB activation. These signaling pathways are known to be 
pathophysiologically relevant in HCC cells (Amann et al., 2009; Ito et al., 1998; 
Schmitz et al., 2008; Nakano et al., 1998; Arsura and Cavin, 2005; Pikarsky et al., 
2004), and in line with this, both extracts also revealed inhibitory effects on 
proliferation and migration of HCC cells in vitro. Importantly, we could exclude that 
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the observed effects derived from remnant lipophilic compounds in hop extracts. 
However and interestingly, individual anti-tumorigenic effects were stronger upon 
stimulation with β-extract compared to α-extract-mediated effects. One might 
speculate that the additional isoprenyl side chain of β-BA, which contributes to a 
higher lipophilicity and increased steric hindrance, may positively influence their 
effects on HCC cells. However, Cattor et al. demonstrated a fast and effective 
uptake of α-BA into colon cancer cells in vitro (Cattoor et al., 2010). Furthermore 
and notwithstanding the slight differences between α- and β-BA regarding anti-
tumorigenic effects on HCC, it has to be noted that α-BA are the most abundant 
type of BA in beer whereas β-BA are only present in trace amounts (Foster et al., 
2009). Still, different methods were developed to isolate BA from hop cones in 
large quantities (i.e. using liquid supercritical carbon dioxide), and thus, 
independent of beer intake, extracts enriched for either α- or β-BA may be 
potentially used as hepatoprotective dietary supplement. 
In the previous chapter it has been described that available studies indicate a high 
safety profile of BA. Still, it has to be considered that HCC mainly develops in 
cirrhotic livers (Kirchner et al., 2010), which are characterized by an impaired 
metabolic and detoxifying capacity. Therefore, special caution has to be taken in 
patients with chronic liver disease, and further studies in experimental fibrosis and 
HCC models are required. Still, the present study indicates the potential of BA as 
functional nutrient for both prevention and treatment of HCC. 
 
5.3 Poor recovery of hop bitter acids in animal chow 
supplemented with a bitter acid-extract 
For a more advanced insight into the bioavailability and safety profile of BA more 
in vivo studies would be wanted. Further, it would have been desirable to verify the 
beneficial effects of BA seen in vitro in the in vivo situation.  
Mice and rats are the most frequently used species to experimentally mimic 
hepatic fibrosis and hepatocancerogenesis. Established models are for example 
the bile duct ligation model or chronic toxic liver injury applying carbon 
tetrachloride or thioacetamide (Brenner, 2009). Further, models leading to non-
alcoholic steatohepatitis (NASH) are increasingly getting attention (Nagarajan et 
al., 2012). All these models last at least several weeks. Rodent models leading to 
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hepatocellular carcinoma (HCC) last even longer. In the diethylnitrosamine (DEN) 
model, the most frequently used model of HCC, tumors develop usually about 8-
12 month after intraperitoneal injection of DEN into young mice. Due to these long 
time spans, it is not practicable to apply or test experimental substances (e.g. hop 
extracts) by repeated intravenous or intraperitoneal injections, respectively. In any 
case, oral application is most desirable also with regards to clinical application 
since the course of liver disease in men typically last several years. Moreover, as 
described above, based on the anatomical situation oral application of BA is 
reasonable for liver diseases. Still, also gavage is not possible due to the long 
experimental duration of the models. Moreover, the administration of BA in water 
is also not practical, because the hydrophobic BA are poorly soluble in water 
(Simpson and Smith, 1992). Thus, we intended to generate a chow supplemented 
with BA extracts to test the efficacy of BA in a defined concentration in established 
rodent models. Here, we used a concentration of 1.75 % (m/m) of BA-extract. This 
can be translated into a daily dose of approximately 1.6 g/day/bodyweight for α-
acids and 0.6 g/day/bodyweight for β-acids, respectively. This concentration is in 
the range of concentrations used in previous studies in men and mice (Mannering 
et al., 1992; Farber et al., 1950). 
Mice are active during night and eat more or less continuously over the 12 hours 
of darkness if housed under controlled conditions with day/night cycles, resulting in 
a mainly steady calorie intake over these 12 hours. Mice are usually housed at a 
temperature of about 20 °C. For logistical reasons food has to be provided in one-
day-portions (or 2- to 3-days-portions on weekends), and therefore, cannot be 
stored continuously at -20 °C. 
Our analysis revealed that even under optimal practical storage conditions, i.e. 
storage at -20 °C, only 75 % of genuine α-acids (n-,co-,ad-) and about 58 % of 
genuine β-acids (n-,co-,ad-) could be recovered after 2 months of storage. 
Currently, we can only speculate whether this loss occurred already during the 
transport and production process. However and remarkably, the recovery even 
further dropped below 10 % for genuine α-acids (n-,co-,ad-) and 4 % for genuine 
β-acids (n-,co-,ad-) if the chow was stored at 4 °C. Although not systematically 
tested, one can speculate that the concentrations of BA would be even lower if 
stored at room temperature, e.g. during application.  
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In addition to the uncertain amount of actually applied BA, the formation of ill-
defined degradation products, which may have unknown biological effects, depicts 
another potential problem. A first evidence for the formation of degradation 
products was the observed increase of humulinic-acid derivates and hulupones as 
the main degradation products of α- and β-acids, respectively, when stored at 
4 °C. Stability or degradation problems, respectively, may also be the reason that 
different studies with the same hop compounds are often difficult to compare. 
These data show that at least with the formulation and the hop extract used here, 
respectively, this chow is not suitable for analyzing the effects of a defined 
concentration of BA in vivo. Together, these data prompted us not to proceed with 
in vivo experiments in which we could have tested the (beneficial) effect of BA-
application in rodent models of (chronic) liver injury. For a sound interpretation and 
comparison of studies it appears mandatory that further approaches have to be 
performed to achieve this goal.  
 
5.4 Conclusion 
Hop bitter acids are multipotent bioactive compounds, however, no data 
concerning the effects on liver cells or liver diseases, respectively, are available at 
present. We could demonstrate that hop bitter acids exhibit beneficial effects on 
hepatic stellate cells as central mediators of liver fibrogenesis as well as on 
hepatocellular carcinoma cells in vitro. Importantly, there is a direct link between 
the pro-fibrogenic phenotype of hepatic stellate cells and the development and 
aggressiveness of hepatocellular carcinoma progression. Furthermore, recent 
reports indicate that bitter acids have a positive effect on lipid metabolism, glucose 
tolerance and insulin resistance in animals. Since metabolic disorders steadily 
increase all over the world leading to chronic liver inflammation and consequently 
to liver damage, hop bitter acids might be an attractive natural drug in the battle 
against chronic liver diseases. Still, further studies are needed to verify the 
beneficial effects in experimental models of liver injury in vivo. However, our 
studies with a BA supplemented chow for rodents revealed a bad stability of BA. 
Therefore, special care has to be taken and the stability of BA has to be monitored 
during in vivo application. Nevertheless, based on the very promising data 
revealed in this thesis with regards to the anti-fibrotic and anti-tumorigenic effects 
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of BA in vitro, it appears worth to emphasize in vivo approaches to study the 
potential of BA as functional nutrient in chronic liver disease. 
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7 Abbreviations 
 
AOM   azoxymethane  
α-sma   α-smooth muscle actin 
AST   aspartate aminotransferase 
AP-1   activator protein-1 
BA   bitter acids 
BW   body weight 
°C   degree Celsius 
cDNA   complementary DNA 
col I   collagen type I 
COX1   cyclooxygenase 1 
COX2   cyclooxygenase 2 
CREB   cAMP response element-binding protein 
Ctr   control 
d   day 
DAPI   4',6-diamidino-2-phenylindole 
DMEM  Dulbecco’s modified eagle medium 
DMSO  dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
ECM   extracellular matrix 
EDTA   ethylene diamine tetraacetic acid 
ED50   effective dose (half-maximal inhibitory dose) 
e.g.   exempli gratia 
EGTA   ethylene glycol tetraacetic acid 
ELISA   enzyme-linked immunosorbent assay 
EMSA   electromobility shift assay 
ERK   extracellular-signal-regulated kinases 
et al.   et alii 
FCS   fetal calf serum 
g   gram 
G   gravitational acceleration 
GRα   glucocorticoid receptor α  
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GOT   glutamic oxaloacetic transaminase 
GPT   glutamic pyruvic transaminase 
h   hour 
HCC   hepatocellular carcinoma 
HDL   high density lipoprotein 
HL-60   premyocytic leukemia cell line 
HPLC   high pressure liquid chromatography 
HSC   hepatic stellate cells 
HRP   horse radish peroxidise 
IC50   half-maximal inhibitory concentrations 
ID50   half-maximal inhibitory dose 
IHE   isomerized α-acid extract 
IκBα   inhibitory kappa B alpha 
IKK   IκB kinase 
IL-6   interleukin-6 
INF γ   interferon γ 
IVC   vena cava inferior 
JNK   c-Jun N-terminal kinases 
KGF    keratinocyte growth factor 
l   liter 
LPS   lipopolysaccharide 
LSEC   liver sinusoidal endothelial cells  
M   molar; mol/l 
mA   miliampere 
MAPK   mitogen-activated protein kinases  
MC3T3-E1   murine osteoblastic cell line 
MCP-1  monocyte chemotactic protein; CCL-2 
META060  tetrahydro-iso-α-acids 
mg   milligram 
min   minute 
mM   milimolar 
m/m   mass per mass 
MMPs   matrix metalloproteinases 
mRNA  messenger ribonucleic acid 
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nm   nanometer 
µg   microgram 
µl   microliter 
µm   micrometer 
NAFLD  non-alcoholic fatty liver disease 
NASH   non-alcoholic steatohepatitis 
NOAEL  no-observed-adverse-effect levels 
NSAIDs   nonsteroidal anti-inflammatory drugs  
NFκB    nuclear factor kappa B  
PBS   phosphate buffered saline 
PDGF   plated derived growth factor 
PGE2   prostaglandin E2 
PI3K    phosphatidylinositol 3-kinase  
PPAR   peroxisome proliferator-activated receptor 
PXR   pregnane X receptor  
q-RT-PCR  quantitative real time PCR 
Rf   retention factor 
RIAA   rho-iso-α-acids  
RNA   ribonucleic acid 
RT-PCR  reverse transcription PCR 
s   second 
TIMPs  tissue inhibitors of metalloproteinases 
TNF α   tumor necrosis factor α 
TPA   12-O-tetradecanoylphorbol-13-acetate 
TRAIL   TNF-related apoptosis inducing ligand  
U   unit 
V   volt 
VEGF   vascular endothelial growth factor 
v/m   volume per mass 
v/v   volume/volume 
WBA    whole blood assays  
w/v   weight per volume 
XN   xanthohumol 
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